


for application to rectal, vaginal, nasal or oral mucosa. In addition to the other materials listed above for systemic administration, thickening agents, emollients, and Gil stabilizers can be used to prepare topical compositions. Examples of thickening agents include petrolatum, beeswax, xanthan gum, or polyethylene, humectants such as sorbitol, emollients such as mineral oil, lanolin and its derivatives, or squalene.

[0450] Modifications and variations of the present invention relating to compounds that inhibit the suppression of VCAM-1 and methods of treating diseases mediated by the expression of VCAM-1 will be obvious to those skilled in the art from the foregoing detailed description of the invention. Such modifications and variations are intended to come within the scope of the appended claims.


We claim:

1. A compound of the formula




or a pharmaceutically acceptable salt or ester thereof.

2. A compound of the formula



or a pharmaceutically acceptable salt thereof.

3. A pharmaceutical composition comprising a compound of the formula



together with a pharmaceutically acceptable carrier.

4. The pharmaceutical composition of claim 3, wherein the pharmaceutically acceptable carrier is suitable for oral administration.

5. The pharmaceutical composition of claim 3, wherein the pharmaceutically acceptable carrier is suitable for topical administration.

6. The pharmaceutical composition of claim 3, wherein the pharmaceutically acceptable carrier is suitable for intravenous administration.

7. The pharmaceutical composition of claim 3, wherein the pharmaceutically acceptable carrier is suitable for subcutaneous administration.

8. The pharmaceutical composition of claim 3, wherein the pharmaceutically acceptable carrier is suitable for intraperitoneal administration.


9. The pharmaceutical composition of claim 3, wherein the pharmaceutically acceptable carrier is suitable for intramuscular administration.

10. The pharmaceutical composition of claim 3, wherein the pharmaceutically acceptable carrier is suitable for submucosal administration.

11. The pharmaceutical composition of claim 3, wherein the pharmaceutically acceptable carrier is suitable for inhalation administration.

12. The pharmaceutical composition of claim 3, wherein the pharmaceutically acceptable carrier is suitable for transdermal administration.

13. A method for the treatment of an inflammatory disorder, comprising administering to a host in need thereof an effective treatment amount of a compound of the formula



or a pharmaceutically acceptable salt thereof.

14. The method of claim 13, wherein the inflammatory disorder is arthritis.

15. The method of claim 13, wherein the inflammatory disorder is rheumatoid arthritis.

16. The method of claim 13, wherein the inflammatory disorder is osteoarthritis.


17. The method of claim 13, wherein the inflammatory disorder is asthma.

18. The method of claim 13, wherein the inflammatory disorder is dermatitis.

19. The method of claim 13, wherein the inflammatory disorder is multiple sclerosis.


20. The method of claim 13, wherein the inflammatory disorder is psoriasis.

21. A method for the treatment of a disorder mediated by VCAM-1, comprising administering to a host in need thereof an effective treatment amount of a compound of the formula



or a pharmaceutically acceptable salt thereof.

22. A method for the treatment of a cardiovascular disorder, comprising administering to a host in need thereof an effective treatment amount of a compound of the formula




or a pharmaceutically acceptable salt thereof.

23. The method of claim 22, wherein the cardiovascular disorder is selected from the group consisting of atherosclerosis, post-angioplasty restenosis, coronary artery disease, angina and small artery disease.

24. A method for suppressing the expression of a redox-sensitive gene or activating a gene that is suppressed through


a redox-sensitive pathway, comprising administering to a host in need thereof an effective treatment amount of a compound of the formula



or a pharmaceutically acceptable salt thereof.

25. The method of claim 24, wherein the redox-sensitive gene expresses cytokines.

26. A method of treating an immune response, comprising administering to a host in need thereof an effective treatment amount of a compound of the formula



or a pharmaceutically acceptable salt thereof.

\* \* \* \* \*

=> s alditol/cn

L1 0 ALDITOL/CN

=> s alditol

8 ALDITOL

1 ALDITOLS

L2 8 ALDITOL

(ALDITOL OR ALDITOLS)

=> d scan

L2 8 ANSWERS REGISTRY COPYRIGHT 2003 ACS

IN DNA (synthetic Streptomyces strain IKD472 alditol oxidase-specific probe) (9CI)

SQL 66

MF Unspecified

CI MAN

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

\*\*\* USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE \*\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):10

L2 8 ANSWERS REGISTRY COPYRIGHT 2003 ACS

IN Oxidase, alditol (Streptomyces strain IKD472 N-terminal fragment) (9CI)

SQL 240

MF Unspecified

CI MAN

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

\*\*\* USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE \*\*\*

L2 8 ANSWERS REGISTRY COPYRIGHT 2003 ACS

IN Carbohydrates and Sugars, hexitols, anhydro

MF Unspecified

CI MAN, CTS

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

L2 8 ANSWERS REGISTRY COPYRIGHT 2003 ACS

IN Oxidase, alditol (Streptomyces strain IKD472) (9CI)

SQL 415

MF Unspecified

CI MAN

\*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\*

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

\*\*\* USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE \*\*\*

L2 8 ANSWERS REGISTRY COPYRIGHT 2003 ACS

IN Oxidase, alditol (9CI)

MF Unspecified

CI MAN

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

L2 8 ANSWERS REGISTRY COPYRIGHT 2003 ACS

IN DNA ( Streptomyces strain IKD472 alditol oxidase gene) (9CI)

SQL 1245  
MF Unspecified  
CI MAN

\*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\*


\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*  
\*\*\* USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE \*\*\*

L2 8 ANSWERS REGISTRY .COPYRIGHT 2003 ACS  
IN DNA (Streptomyces strain IKD472 alditol oxidase N-terminal  
fragment-specifying gene) (9CI)  
SQL 720  
MF Unspecified  
CI MAN

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*  
\*\*\* USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE \*\*\*

L2 8 ANSWERS REGISTRY .COPYRIGHT 2003 ACS  
IN 1,2,3,4-Cyclopentanetetrol, 5-[(2S)-2,3-dihydroxypropoxy]-1-  
(hydroxymethyl)-, (1S,2R,3R,4R,5S)- (9CI)  
MF C9 H18 O8

Absolute stereochemistry.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

ALL ANSWERS HAVE BEEN SCANNED



ACCESSION NUMBER: 1998:761875 CAPLUS  
 DOCUMENT NUMBER: 130:13646  
 TITLE: Preparation of phenolic compounds for the inhibition of the expression of VCAM-1  
 INVENTOR(S): Medford, Russell M.; Somers, Patricia K.; Hoong, Lee K.; Meng, Charles Q.  
 PATENT ASSIGNEE(S): Atherogenics, Inc., USA  
 SOURCE: PCT Int. Appl., 109 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 4  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9851662	A2	19981119	WO 1998-US9781	19980514
WO 9851662	A3	20000302		
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9874851	A1	19981208	AU 1998-74851	19980514
AU 750041	B2	20020711		
EP 994853	A2	20000426	EP 1998-922264	19980514
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
US 6121319	A	20000919	US 1998-78935	19980514
BR 9809819	A	20010918	BR 1998-9819	19980514
JP 2002503227	T2	20020129	JP 1998-549502	19980514
NO 9905544	A	20000110	NO 1999-5544	19991112
MX 9910402	A	20000630	MX 1999-10402	19991112
PRIORITY APPLN. INFO.:			US 1997-47020P	P 19970514
			WO 1998-US9781	W 19980514
OTHER SOURCE(S):		MARPAT 130:13646		
GI				



AB Title compds. [e.g., I; R = Z1Z2R5; R1, R2 = (un)substituted (cyclo)alkyl, -(hetero)aryl, etc.; R3, R4 = any group that does not otherwise adversely affect (sic) the desired properties of the mol. including H, halogen, or R1 (sic); R5 = (di)(alkyl)amino, alkyl, alkoxy(carbonyl), (hetero)aryl, etc.; Z1 = O SOO-2, NH, CH2; Z2 = bond, alkylene(oxy) aryleneoxy, etc.] were prepd. Thus, 4-(BrCH2)C6H4CH2CO2H was thioetherified by 4-mercapto-2,6-di-tert-butylphenol to give I [R = SCH2C6H4(CH2CO2H)-4, R1 = R2 = CMe3, R3 = R4 = H]. Data for biol. activity of I were given.


IT 216168-01-3P 216168-36-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of phenolic compds. for the inhibition of the expression of VCAM-1)

RN 216168-01-3 CAPLUS


CN 1,2,3-Butanetriol, 4-[4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenoxy]-(9CI) (CA INDEX NAME)



RN 216168-36-4 CAPLUS

CN D-Glucitol, 6-O-[4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenyl]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



ACCESSION NUMBER: 1998:761875 CAPLUS  
 DOCUMENT NUMBER: 130:13646  
 TITLE: Preparation of phenolic compounds for the inhibition of the expression of VCAM-1  
 INVENTOR(S): Medford, Russell M.; Somers, Patricia K.; Hoong, Lee K.; Meng, Charles Q.  
 PATENT ASSIGNEE(S): Atherogenics, Inc., USA  
 SOURCE: PCT Int. Appl., 109 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 4  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9851662	A2	19981119	WO 1998-US9781	19980514
WO 9851662	A3	20000302		
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9874851	A1	19981208	AU 1998-74851	19980514
AU 750041	B2	20020711		
EP 994853	A2	20000426	EP 1998-922264	19980514
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
US 6121319	A	20000919	US 1998-78935	19980514
BR 9809819	A	20010918	BR 1998-9819	19980514
JP 2002503227	T2	20020129	JP 1998-549502	19980514
NO 9905544	A	20000110	NO 1999-5544	19991112
MX 9910402	A	20000630	MX 1999-10402	19991112
PRIORITY APPLN. INFO.:			US 1997-47020P	P 19970514
			WO 1998-US9781	W 19980514

OTHER SOURCE(S): MARPAT 130:13646  
 GI



AB Title compds. [e.g., I; R = Z1Z2R5; R1,R2 = (un)substituted (cyclo)alkyl, -(hetero)aryl, etc.; R3,R4 = any group that does not otherwise adversely affect (sic) the desired properties of the mol. including H, halogen, or R1 (sic); R5 = (di)(alkyl)amino, alkyl, alkoxy(carbonyl), (hetero)aryl, etc.; Z1 = O SOO-2, NH, CH2; Z2 = bond, alkylene(oxy) aryleneoxy, etc.] were prep'd. Thus, 4-(BrCH2)C6H4CH2CO2H was thioetherified by 4-mercapto-2,6-di-tert-butylphenol to give I [R = SCH2C6H4(CH2CO2H)-4, R1 = R2 = CMe3, R3 = R4 = H]. Data for biol. activity of I were given.


IT 216168-01-3P 216168-36-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of phenolic compds. for the inhibition of the expression of VCAM-1)

RN 216168-01-3 CAPLUS


CN 1,2,3-Butanetriol, 4-[4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenoxy]-(9CI) (CA INDEX NAME)



RN 216168-36-4 CAPLUS

CN D-Glucitol, 6-O-[4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenyl]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



ACCESSION NUMBER: 1998:761875 CAPLUS  
 DOCUMENT NUMBER: 130:13646  
 TITLE: Preparation of phenolic compounds for the inhibition of the expression of VCAM-1  
 INVENTOR(S): Medford, Russell M.; Somers, Patricia K.; Hoong, Lee K.; Meng, Charles Q.  
 PATENT ASSIGNEE(S): Atherogenics, Inc., USA  
 SOURCE: PCT Int. Appl., 109 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 4  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9851662	A2	19981119	WO 1998-US9781	19980514
WO 9851662	A3	20000302		
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9874851	A1	19981208	AU 1998-74851	19980514
AU 750041	B2	20020711		
EP 994853	A2	20000426	EP 1998-922264	19980514
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
US 6121319	A	20000919	US 1998-78935	19980514
BR 9809819	A	20010918	BR 1998-9819	19980514
JP 2002503227	T2	20020129	JP 1998-549502	19980514
NO 9905544	A	20000110	NO 1999-5544	19991112
MX 9910402	A	20000630	MX 1999-10402	19991112
PRIORITY APPLN. INFO.:			US 1997-47020P	P 19970514
			WO 1998-US9781	W 19980514

OTHER SOURCE(S): MARPAT 130:13646  
 GI



AB Title compds. [e.g., I; R = Z1Z2R5; R1,R2 = (un)substituted (cyclo)alkyl, -(hetero)aryl, etc.; R3,R4 = any group that does not otherwise adversely affect (sic) the desired properties of the mol. including H, halogen, or R1 (sic); R5 = (di)(alkyl)amino, alkyl, alkoxy(carbonyl), (hetero)aryl, etc.; Z1 = O SOO-2, NH, CH2; Z2 = bond, alkylene(oxy) aryleneoxy, etc.] were prepd. Thus, 4-(BrCH2)C6H4CH2CO2H was thioetherified by 4-mercapto-2,6-di-tert-butylphenol to give I [R = SCH2C6H4(CH2CO2H)-4, R1 = R2 = CMe3, R3 = R4 = H]. Data for biol. activity of I were given.


IT 216168-01-3P 216168-36-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of phenolic compds. for the inhibition of the expression of VCAM-1)

RN 216168-01-3 CAPLUS


CN 1,2,3-Butanetriol, 4-[4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenoxy]-(9CI) (CA INDEX NAME)



RN 216168-36-4 CAPLUS

CN D-Glucitol, 6-O-[4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenyl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




L1 STRUCTURE UPLOADED

=> d

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 11:12:57 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 22 TO ITERATE

100.0% PROCESSED 22 ITERATIONS

7 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*

BATCH \*\*COMPLETE\*\*

PROJECTED ITERATIONS: 159 TO 721

PROJECTED ANSWERS: 7 TO 298

L2 7 SEA SSS SAM L1


=> d scan

L2 7 ANSWERS REGISTRY COPYRIGHT 2003 ACS

IN 2-Butenedioic acid (2Z)-, mono[4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenyl] ester (9CI)

MF C35 H50 O5 S2

Double bond geometry as shown.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> s l1 full

FULL SEARCH INITIATED 11:13:08 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 456 TO ITERATE

100.0% PROCESSED 456 ITERATIONS

105 ANSWERS

SEARCH TIME: 00.00.01

L3 105 SEA SSS FUL L1


=> d scan

L3 105 ANSWERS REGISTRY COPYRIGHT 2003 ACS

IN Phenol, 4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-[(1E)-3-hydroxy-1-propenyl]oxy]phenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)-(9CI)

MF C34 H52 O3 S2

Double bond geometry as shown.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):10

L3 105 ANSWERS REGISTRY COPYRIGHT 2003 ACS

IN Phenol, 4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-(3-pyridinylmethoxy)phenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)-(9CI)


MF C37 H53 N O2 S2



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*




L3 105 ANSWERS REGISTRY COPYRIGHT 2003 ACS  
 IN 2-Butanone, 1-[4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenoxy]-3,3-dimethyl- (9CI)  
 MF C37 H58 O3 S2



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L3 105 ANSWERS REGISTRY COPYRIGHT 2003 ACS  
 IN Butanedioic acid, 4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenyl methyl ester (9CI)  
 MF C36 H54 O5 S2



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L3 105 ANSWERS REGISTRY COPYRIGHT 2003 ACS  
 IN D-Ribonic acid, 5-O-[4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenyl]-, .gamma.-lactone (9CI)  
 MF C36 H54 O6 S2

Absolute stereochemistry.



=> s 15

L6 1 L5

=> d ibib abs hitstr it

L6 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1991:558965 CAPLUS

DOCUMENT NUMBER: 115:158965

TITLE: Preparation of 6-aryloxymethyl-4-hydroxytetrahydropyran-2-ones and the corresponding dihydroxycarboxylic acids and salts as HMG-CoA reductase inhibitors and biological antioxidants  
INVENTOR(S): Jendralla, Heiner; Wess, Guenther; Kessler, Kurt; Beck, Gerhard

PATENT ASSIGNEE(S): Hoechst A.-G., Germany

SOURCE: Eur. Pat. Appl., 59 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: German


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 418648	A1	19910327	EP 1990-117043	19900905
EP 418648	B1	19950111		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
DE 3929913	A1	19910404	DE 1989-3929913	19890908
ES 2067609	T3	19950401	ES 1990-117043	19900905
US 5294724	A	19940315	US 1990-578240	19900906
CA 2024849	AA	19910309	CA 1990-2024849	19900907
CA 2024849	C	20020101		
NO 9003911	A	19910311	NO 1990-3911	19900907
NO 175002	B	19940509		
NO 175002	C	19940817		
AU 9062277	A1	19910314	AU 1990-62277	19900907
AU 629977	B2	19921015		
JP 03099075	A2	19910424	JP 1990-235998	19900907
JP 3053417	B2	20000619		
ZA 9007134	A	19910626	ZA 1990-7134	19900907
HU 56085	A2	19910729	HU 1990-5827	19900907
HU 212103	B	19960228		
IL 95599	A1	19990714	IL 1990-95599	19901006
FI 9603396	A	19960830	FI 1996-3396	19960830
PRIORITY APPLN. INFO.:			DE 1989-3929913	A 19890908
			FI 1990-4395	A 19900906

OTHER SOURCE(S): MARPAT 115:158965

GI



AB Title compds. [I; X, Y = O, S; R1, R5 = Me2CH, cyclopropyl, (un)substituted Ph; R2, R4 = H, Me2CH, cyclopropyl, (un)substituted Ph; R3 = H, Me, Et, C3-8 alkyl optionally substituted by thiophenyl residue Q in which X, R1, R2, R4, R5 are as above, Z = H, pharmaceutically compatible cation, hydroxypyranyl residue Q1, dihydroxyhexanoic acid residue Q2 (R6 = OH, R7 = H), C3-8 cycloalkyl, (un)substituted Ph, acetyl (when Y = O)], open chain carboxylic acid forms (II; R1-R5, X, Y as defined) and their pharmaceutically compatible esters or salts with bases, useful as antihypercholesteremics and for the prophylaxis and treatment of arteriosclerosis, were prepd. Reaction of 2-(p-fluorophenyl)-4-isothiocyanato-6-isopropylphenol (prepn. given) with 4-FC6H4MgBr gave 100% phenylthiophenol deriv. which underwent a substitution reaction (74.0%) with 6-mesyloxydihydroxyhexanoate tert-Bu ester acetone Q2OSO2Me (R6 = CMe3, R7R7 = CMe2). The product was deprotected (80.8%) and saponified to give 93% the title compd. 3(R),5(S)-dihydroxy-6-[2-p-fluorophenyl-4-p-fluorophenylthio-6-isopropyl]phenoxyhexanoate Na salt (III). The latter in vitro inhibited rat liver microsomal HMG CoA reductase with IC50 of 6 .times. 10-9 M, vs. 8 .times. 10-9 M for mevinolin Na salt.


IT **136315-18-9P**

RL: SPN (Synthetic preparation); PREP (Preparation)  
(prepn. of, as HMG-CoA reductase inhibitor and biol. antioxidant)

RN 136315-18-9 CAPLUS

CN D-erythro-Hexonic acid, 2,4-dideoxy-6-O-[4'-fluoro-5-[[1-[[4'-fluoro-6-hydroxy-5-(1-methylethyl)[1,1'-biphenyl]-3-yl]thio]-1-methylethyl]thio]-3-(1-methylethyl)[1,1'-biphenyl]-2-yl]-, sodium salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●x Na

- IT Antioxidants  
(biol., (aryloxymethyl)hydroxypyranones)
- IT Anticholesteremics and Hypolipemics  
(hydroxytetrahydropyranones)
- IT Arteriosclerosis  
(treatment and prophylaxis of, prepn. of (aryloxymethyl)hydroxytetrahydropyranones for)
- IT 100-18-5, 1,4-Diisopropylbenzene  
RL: RCT (Reactant); RACT (Reactant or reagent)  
(acetylation of)
- IT 51437-00-4  
RL: RCT (Reactant); RACT (Reactant or reagent)  
(arylation by, of bromo(isopropyl)phenol, in prepn. of drug)
- IT 460-00-4, p-Bromofluorobenzene  
RL: RCT (Reactant); RACT (Reactant or reagent)  
(arylation by, of isopropylphenol, in prepn. of drug)
- IT 129976-32-5, 2-Bromo-6-isopropylphenol  
RL: RCT (Reactant); RACT (Reactant or reagent)  
(arylation of, by bromofluorobenzene deriv., in prepn. of drug)
- IT 10292-60-1, o-Cyclopropylphenol  
RL: RCT (Reactant); RACT (Reactant or reagent)  
(bromination of)
- IT 88-69-7, o-Isopropylphenol  
RL: RCT (Reactant); RACT (Reactant or reagent)  
(bromination of, in prepn. of drug)
- IT 541-41-3, Ethyl chloroformate  
RL: RCT (Reactant); RACT (Reactant or reagent)  
(esterification by, and lactonization, of hexanoic acid deriv.)
- IT 67-63-0, 2-Propanol, reactions  
RL: RCT (Reactant); RACT (Reactant or reagent)  
(etherification by, of thiocyanatophenol deriv.)
- IT 136007-98-2P 136007-99-3P  
RL: FORM (Formation, nonpreparative); PREP (Preparation)  
(formation of, in acetylation of triisopropyl hydroquinone deriv.)
- IT 136216-06-3P  
RL: FORM (Formation, nonpreparative); PREP (Preparation)  
(formation of, in deprotection of (isopropylidenethio)bisfluorophenylbenzene deriv.)
- IT 136216-04-1P 136216-05-2P  
RL: FORM (Formation, nonpreparative); PREP (Preparation)  
(formation of, in substitution reaction of fluorophenylphenol deriv. by mesyl dihydrohexanoate ester deriv.)
- IT 9028-35-7, HMG-CoA reductase  
RL: USES (Uses)  
(inhibitors, prepn. of arylhydroxytetrahydropyranone derivs. as)

IT 131003-19-5P, 2-(p-Fluorophenyl)-3,5,6-triisopropyl-1,4-hydroquinone  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (prepn. and acetylation of, in prepn. of drug)

IT 129976-32-5P, 2-Bromo-6-isopropylphenol  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (prepn. and arylation of, by bromofluorobenzene deriv.)

IT 131003-16-2P, 1-Bromo-2,4,5-triisopropylbenzene  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (prepn. and arylation of, by bromofluorobenzene, in prepn. of drug)

IT 136215-86-6P, 2-Bromo-6-cyclopropylphenol  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (prepn. and arylation of, with bromofluorobenzene)

IT 136215-94-6P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (prepn. and bromination of, in prepn. of drug)

IT 136215-91-3P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (prepn. and conversion of, to phenylthio deriv)

IT 136215-88-8P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (prepn. and conversion of, to phenylthio deriv, in prepn. of drug)

IT 136215-93-5P, 1-(2-Hydroxy-2-propyl)-2,5-diisopropylbenzene  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (prepn. and dehydration of, in prepn. of drug)

IT 948-32-3P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (prepn. and dehydrogenation of)

IT 136006-85-4P 136006-86-5P 136006-87-6P 136034-10-1P 136215-95-7P  
 136215-96-8P 136215-98-0P 136216-00-7P 136216-02-9P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (prepn. and deprotection of, in prepn. of drug)

IT 136315-22-5P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (prepn. and lactonization of, in prepn. of drug)

IT 131003-17-3P, 1-(p-Fluorophenyl)-2,4,5-triisopropylbenzene  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (prepn. and oxidn. of, in prepn. of drug)

IT 77344-62-8P, 1-Acetyl-2,5-diisopropylbenzene  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (prepn. and reaction of, with methylmagnesium iodide)

IT 131003-18-4P, 2-(p-Fluorophenyl)-3,5,6-triisopropyl-1,4-benzoquinone  
 131003-20-8P, 2-(p-Fluorophenyl)-4-thiocyanato-6-isopropylphenol  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (prepn. and redn. of, in prepn. of drug)

IT 135054-68-1P 135054-70-5P 136006-89-8P 136006-90-1P 136006-91-2P  
 136006-92-3P 136215-97-9P 136215-99-1P 136216-01-8P 136216-03-0P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (prepn. and sapon. of, in prepn. of drug)

IT 131003-22-0P 136249-38-2P 136249-39-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (prepn. and substitution reaction of, with mesyl dihydroxyhexanoate ester)

IT 136007-97-1P, 2,5,6-Triisopropyl-3-(p-fluorophenyl)-4-acetoxyphenol  
 136215-89-9P 136215-92-4P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (prepn. and substitution reaction of, with mesyl dihydroxyhexanoate ester deriv.)

IT 131003-09-3P 136215-90-2P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (prepn. and thiocyanation of)

IT 136215-87-7P, 2-(p-Fluorophenyl)-6-cyclopropylphenol  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (prepn. and thlocyanation of, in prepn. of drug)

IT 131003-21-9P, 2-(p-Fluorophenyl)-4-mercapto-6-isopropylphenol  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (prepn. and thioetherification of, by dimethoxypropane, in prepn. of drug)

IT 135054-71-6P 136215-82-2P 136215-83-3P 136215-84-4P 136215-85-5P  
**136315-18-9P** 136315-19-0P 136315-20-3P 136315-21-4P  
 136316-20-6P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (prepn. of, as HMG-CoA reductase inhibitor and biol. antioxidant)

IT 131003-24-2P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (prepn. of, as intermediate for antihypercholesteremic/antioxidant)

IT 100-58-3, Phenylmagnesium bromide  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (reaction of, with thiocyanatophenol deriv., in prepn. of drug)

IT 135054-68-1  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (substitution reaction of, with phenol derivs., in prepn. of HMG-CoA reductase inhibitors and biol. antioxidants)

=> s 15 and C37 H60 O7 S2/mf

# **REGISTRY INITIATED**

Substance data SEARCH and crossover from CAS REGISTRY in progress...

Use DISPLAY HITSTR (or FHITSTR) to directly view retrieved structures.

1 3 L3 AND C37 H60 O7 S2/MF

=> d 1-3

L11 ANSWER 1 OF 3 REGISTRY COPYRIGHT 2003 ACS

RN 473427-26-8 REGISTRY


CN Hexitol, 6-O-[4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenyl]- (9CI) (CA INDEX NAME)

FS 3D CONCORD

MF C37 H60 O7 S2

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1957 TO DATE)

1 REFERENCES IN FILE CAPLUS (1957 TO DATE)

L11 ANSWER 2 OF 3 REGISTRY COPYRIGHT 2003 ACS

RN 366494-65-7 REGISTRY

CN D-Altritol, 1-O-[4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenyl]- (9CI) (CA INDEX NAME)


FS STEREOSEARCH

MF C37 H60 O7 S2

SR CA

LC STN Files: CA, CAPLUS, USPATFULL

Absolute stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1957 TO DATE)

1 REFERENCES IN FILE CAPLUS (1957 TO DATE)

L11 ANSWER 3 OF 3 REGISTRY COPYRIGHT 2003 ACS

RN 216168-36-4 REGISTRY

CN D-Glucitol, 6-O-[4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-

1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenyl]- (9CI) (CA INDEX NAME)


FS STEREOSEARCH

MF C37 H60 O7 S2

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

3 REFERENCES IN FILE CA (1957 TO DATE)

3 REFERENCES IN FILE CAPLUS (1957 TO DATE)

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
13.88	211.23

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
0.00	-0.65

CA SUBSCRIBER PRICE

FILE 'CAPLUS' ENTERED AT 11:19:21 ON 25 MAY 2003

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 25 May 2003 VOL 138 ISS 22

FILE LAST UPDATED: 23 May 2003 (20030523/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l11

L12 4 L11

=> d ibib abs hitstr 1-4 it



L12 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2002:814837 CAPLUS

DOCUMENT NUMBER: 137:320305

TITLE: Probucol derivatives and methods for treating transplant rejection

INVENTOR(S): Edwards, David B.; Somers, Patricia K.; Glass, Mitchell

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 22 pp., Cont.-in-part of U.S. Ser. No. 815,262.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 4

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002156022	A1	20021024	US 2001-36307	20011025
US 6147250	A	20001114	US 1998-79213	19980514
US 6548699	B1	20030415	US 1999-370046	19990806
US 2002016300	A1	20020207	US 2001-815262	20010321
US 2002177717	A1	20021128	US 2002-60734	20020130
US 2002169215	A1	20021114	US 2002-114346	20020402
US 2002188118	A1	20021212	US 2002-115206	20020402
US 2002193446	A1	20021219	US 2002-114351	20020402
PRIORITY APPLN. INFO.:			US 1997-47020P	P 19970514
			US 1998-79213	A1 19980514
			US 1999-370046	A2 19990806
			US 2000-191046P	P 20000321
			US 2001-815262	A2 20010321

OTHER SOURCE(S): MARPAT 137:320305

GI



AB The invention discloses the use of I [R1-R4 = H, OH, C1-10 alkyl, aryl, heteroaryl, etc.; Y = bond, C(O); Z = C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, etc.], and pharmaceutically acceptable salts thereof, alone or in combination, for the treatment of transplant rejection. Prepn. of I [R1-R4 = tert-butyl; YZ = (CH2)3COOH] from probucol which was evaluated in a graft arteriopathy model and Me 4-chlorobutyrate is described.


IT **216168-36-4 473427-26-8**

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(probucol derivs. for treatment of transplant rejection)

RN 216168-36-4 CAPLUS


CN D-Glucitol, 6-O-[4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 473427-26-8 CAPLUS

CN. Hexitol, 6-O-[4-[[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenyl]- (9CI) (CA INDEX NAME)



IT Transplant and Transplantation  
(allotransplant, aorta; probucol derivs. for treatment of transplant rejection)

IT Artery  
(aorta, allotransplant; probucol derivs. for treatment of transplant rejection)

IT Arteriosclerosis  
Cell proliferation  
Cytotoxic agents  
Immunosuppressants  
Transplant and Transplantation  
Transplant rejection  
(probucol derivs. for treatment of transplant rejection)

IT Steroids, biological studies  
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(probucol derivs. for treatment of transplant rejection)

IT Blood vessel  
(smooth muscle; probucol derivs. for treatment of transplant rejection)

IT 216167-95-2P  
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
(probucol derivs. for treatment of transplant rejection)

IT 59-05-2, Methotrexate 446-86-6, Azathioprine 24280-93-1, Mycophenolic acid 53123-88-9, Sirolimus 79217-60-0, Cyclosporin 104987-11-3, Tacrolimus 128794-94-5, Mycophenolate mofetil 159351-69-6, Everolimus 216167-82-7 216167-86-1 216167-92-9 216167-93-0 216167-94-1 216168-01-3 216168-28-4 **216168-36-4** 260370-57-8, NOX-100 366494-64-6 **473427-26-8** 473427-29-1  
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(probucol derivs. for treatment of transplant rejection)

IT 3153-37-5, Methyl 4-chlorobutyrate 23288-49-5, Probucol  
RL: RCT (Reactant); RACT (Reactant or reagent)  
(reaction; probucol derivs. for treatment of transplant rejection)

L12 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2001:762965 CAPLUS

DOCUMENT NUMBER: 135:303678

TITLE: Preparation of probucol monoethers which increase plasma HDL cholesterol levels and which improve HDL functionality.

INVENTOR(S): Luchoomun, Jayraz; Meng, Charles Q.; Saxena, Uday

PATENT ASSIGNEE(S): Atherogenics, Inc., USA

SOURCE: PCT Int. Appl., 105 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001077072	A2	20011018	WO 2001-US11899	20010411
WO 2001077072	A3	20020718		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
US 2002016364	A1	20020207	US 2001-833407	20010411
EP 1272465	A2	20030108	EP 2001-926894	20010411
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			

PRIORITY APPLN. INFO.: US 2000-196201P P 20000411

WO 2001-US11899 W 20010411

GI



AB Title compds., e.g. (I), were prepd. Thus, D-ribonic acid .gamma.-lactone was refluxed 16 h with tri-Et orthoformate in THF to give a residue which was refluxed with probucol, Ph3P, and di-Et azodicarboxylate in THF to give a residue which in turn was refluxed with HOAc/MeOH/H2O to give a residue which was stirred with aq. NaOH in THF to give I. I at 150 mg/kg/day gave a 30% increase in HDL cholesterol levels in hypercholesterolemic hamsters. Title compds. may also improve HDL functionality by (a) increasing clearance of cholesteryl esters, (b) increasing HDL-particle affinity for hepatic cell surface receptors or (c) increasing the half life of apoAI-HDL.

IT 366494-65-7


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(prepn. of probucol monoethers which increase plasma HDL cholesterol levels and which improve HDL functionality)

RN 366494-65-7 CAPLUS

CN D-Altritol, 1-O-[4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT Apolipoproteins

RL: BPR (Biological process); BSU (Biological study, unclassified); MSC (Miscellaneous); BIOL (Biological study); PROC (Process)

(A-I, apoAI-HDL half life increase; prepn. of probucol monoethers which increase plasma HDL cholesterol levels and which improve HDL functionality)

IT Lipoproteins

RL: BPR (Biological process); BSU (Biological study, unclassified); MSC (Miscellaneous); BIOL (Biological study); PROC (Process)

(high-d.; prepn. of probucol monoethers which increase plasma HDL cholesterol levels and which improve HDL functionality)

IT 23288-49-5DP, Probucol, monoethers 268738-49-4P 366494-61-3P 366494-62-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of probucol monoethers which increase plasma HDL cholesterol levels and which improve HDL functionality)

IT 216168-00-2 216168-35-3 **366494-65-7**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(prepn. of probucol monoethers which increase plasma HDL cholesterol levels and which improve HDL functionality)

IT 2478-10-6, 4-Hydroxybutyl acrylate 5336-08-3, D-Ribonic acid

.gamma.-lactone 23288-49-5, Probucol

RL: RCT (Reactant); RACT (Reactant or reagent)

(prepn. of probucol monoethers which increase plasma HDL cholesterol levels and which improve HDL functionality)

IT 78508-93-7P 216168-29-5P 216168-30-8P 366494-63-5P 366494-64-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. of probucol monoethers which increase plasma HDL cholesterol levels and which improve HDL functionality)

L12 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2000:335659 CAPLUS

DOCUMENT NUMBER: 132:343330

TITLE: Methods and compositions to lower plasma cholesterol levels

INVENTOR(S): Medford, Russell M.; Saxena, Uday  
 PATENT ASSIGNEE(S): Atherogenics, Inc., USA  
 SOURCE: PCT Int. Appl., 50 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000028332	A1	20000518	WO 1999-US26519	19991109
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1137948	A1	20011004	EP 1999-962732	19991109
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002529740	T2	20020910	JP 2000-581459	19991109
PRIORITY APPLN. INFO.: US 1998-107644P P 19981109				
WO 1999-US26519 W 19991109				

AB A method for detg. whether a compd. binds to a lipoprotein, e.g. LDL or VLDL, in a manner which will lower plasma cholesterol is provided that includes assessing the ability of the compd. to form a complex with the lipoprotein, e.g., LDL or VLDL, and then detg. whether the newly formed complex causes a change in the structure of apoB-100 that results in increased binding affinity to the LDL receptor. Also disclosed is a method for lowering cholesterol in a host in need thereof, including a human, that includes the administration of an effective amt. of a compd. which binds to cholesterol-carrying lipoprotein (e.g. LDL or VLDL) in a manner that alters the three dimensional configuration of the lipoprotein and increases the binding affinity of the apoB-100 protein to the LDL receptor, including those on the surface of a hepatic cell.

IT **216168-36-4**


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(methods and compns. to lower plasma cholesterol levels)

RN 216168-36-4 CAPLUS

CN D-Glucitol, 6-O-[4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT Apolipoproteins

RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)  
 (B-100; methods and compns. to lower plasma cholesterol levels)

IT Animal cell line  
 (Hep G2; methods and compns. to lower plasma cholesterol levels)

IT Liver  
 (LDL receptor of; methods and compns. to lower plasma cholesterol levels)

IT Lipoprotein receptors  
 RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)  
 (LDL; methods and compns. to lower plasma cholesterol levels)

IT Electrophoresis  
 (agarose; methods and compns. to lower plasma cholesterol levels)

IT Phenotypes  
 (apoB-100; methods and compns. to lower plasma cholesterol levels)

IT Sequestering agents  
 (bile acid; methods and compns. to lower plasma cholesterol levels)

IT Immunoassay  
 (enzyme-linked immunosorbent assay, sandwich; methods and compns. to lower plasma cholesterol levels)

IT Lipoproteins  
 RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)  
 (high-d.; methods and compns. to lower plasma cholesterol levels)

IT Lipoproteins  
 RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)  
 (intermediate-d.; methods and compns. to lower plasma cholesterol levels)

IT Lipoproteins  
 RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)  
 (low-d.; methods and compns. to lower plasma cholesterol levels)

IT Anticholesteremic agents  
 Drug screening  
 Epitopes  
 Molecular association  
 (methods and compns. to lower plasma cholesterol levels)

IT Antibodies  
 RL: ARG (Analytical reagent use); ANST (Analytical study); USES (Uses)  
 (monoclonal; methods and compns. to lower plasma cholesterol levels)

IT Conformation  
 (protein; methods and compns. to lower plasma cholesterol levels)

IT Immunoassay  
 (sandwich; methods and compns. to lower plasma cholesterol levels)

IT Bile acids  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (sequestrants; methods and compns. to lower plasma cholesterol levels)

IT Drugs  
 (statins; methods and compns. to lower plasma cholesterol levels)

IT Antibodies  
 RL: ARG (Analytical reagent use); ANST (Analytical study); USES (Uses)  
 (to apoB-100; methods and compns. to lower plasma cholesterol levels)

IT Biological transport  
 (uptake, LDL; methods and compns. to lower plasma cholesterol levels)

IT Lipoproteins  
 RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)  
 (very-low-d.; methods and compns. to lower plasma cholesterol levels)

IT 9012-36-6, Agarose  
 RL: ARU (Analytical role, unclassified); ANST (Analytical study)

(electrophoresis; methods and compns. to lower plasma cholesterol levels)

IT 59-67-6, Nicotinic acid, biological studies 943-45-3D, Fibric acid, derivs. 1404-04-2, Neomycin 11041-12-6, Cholestyramine 23288-49-5, Probucol 25769-03-3, 1-Pyrrolidinecarbodithioic acid 216167-66-7  
216167-67-8 216167-69-0 216167-74-7 216167-82-7 216167-84-9  
216167-91-8 216167-93-0 216167-94-1 216167-95-2 216168-35-3  
**216168-36-4** 216168-42-2 216168-49-9 268738-42-7  
268738-43-8 268738-44-9 268738-45-0 268738-46-1 268738-47-2  
268738-48-3 268738-49-4 268738-50-7 268738-51-8 268738-52-9  
268738-53-0 268738-54-1

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(methods and compns. to lower plasma cholesterol levels)

IT 57-88-5, Cholesterol, biological studies  
RL: BOC (Biological occurrence); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); OCCU (Occurrence); PROC (Process)

(methods and compns. to lower plasma cholesterol levels)

REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1998:761875 CAPLUS

DOCUMENT NUMBER: 130:13646

TITLE: Preparation of phenolic compounds for the inhibition of the expression of VCAM-1

INVENTOR(S): Medford, Russell M.; Somers, Patricia K.; Hoong, Lee K.; Meng, Charles Q.

PATENT ASSIGNEE(S): Atherogenics, Inc., USA

SOURCE: PCT Int. Appl., 109 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 4

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9851662	A2	19981119	WO 1998-US9781	19980514
WO 9851662	A3	20000302		
W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
AU 9874851	A1	19981208	AU 1998-74851	19980514
AU 750041	B2	20020711		
EP 994853	A2	20000426	EP 1998-922264	19980514
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
US 6121319	A	20000919	US 1998-78935	19980514
BR 9809819	A	20010918	BR 1998-9819	19980514
JP 2002503227	T2	20020129	JP 1998-549502	19980514
NO 9905544	A	20000110	NO 1999-5544	19991112
MX 9910402	A	20000630	MX 1999-10402	19991112

PRIORITY APPLN. INFO.: US 1997-47020P P 19970514

WO 1998-US9781 W 19980514

OTHER SOURCE(S): MARPAT 130:13646

GI



AB Title compds. [e.g., I; R = Z1Z2R5; R1,R2 = (un)substituted (cyclo)alkyl, -(hetero)aryl, etc.; R3,R4 = any group that does not otherwise adversely affect (sic) the desired properties of the mol. including H, halogen, or R1 (sic); R5 = (di)(alkyl)amino, alkyl, alkoxy(carbonyl), (hetero)aryl, etc.; Z1 = O SOO-2, NH, CH2; Z2 = bond, alkylene(oxy) aryleneoxy, etc.] were prepd. Thus, 4-(BrCH2)C6H4CH2CO2H was thioetherified by 4-mercapto-2,6-di-tert-butylphenol to give I [R = SCH2C6H4(CH2CO2H)-4, R1 = R2 = CMe3, R3 = R4 = H]. Data for biol. activity of I were given.

IT **216168-36-4P**


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of phenolic compds. for the inhibition of the expression of VCAM-1)

RN 216168-36-4 CAPLUS

CN D-Glucitol, 6-O-[4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT Cell adhesion molecules

RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)

(VCAM-1, mediated disorders; treatment; prepn. of phenolic compds. for the inhibition of the expression of VCAM-1)

IT Anti-inflammatory agents

Cardiovascular agents

(prepn. of phenolic compds. for the inhibition of the expression of VCAM-1)

IT	54622-24-1P	123787-53-1P	141896-35-7P	216167-62-3P	216167-63-4P
	216167-64-5P	216167-65-6P	216167-66-7P	216167-67-8P	216167-68-9P
	216167-69-0P	216167-70-3P	216167-71-4P	216167-72-5P	216167-73-6P
	216167-74-7P	216167-75-8P	216167-76-9P	216167-77-0P	216167-78-1P
	216167-79-2P	216167-80-5P	216167-81-6P	216167-82-7P	216167-83-8P
	216167-84-9P	216167-85-0P	216167-86-1P	216167-88-3P	216167-89-4P
	216167-90-7P	216167-91-8P	216167-92-9P	216167-93-0P	216167-94-1P



216167-95-2P	216167-96-3P	216167-97-4P	216167-98-5P	216167-99-6P
216168-00-2P	216168-01-3P	216168-02-4P	216168-03-5P	216168-05-7P
216168-07-9P	216168-10-4P	216168-12-6P	216168-14-8P	216168-16-0P
216168-18-2P	216168-20-6P	216168-22-8P	216168-24-0P	216168-26-2P
216168-27-3P	216168-28-4P	216168-29-5P	216168-30-8P	216168-31-9P
216168-32-0P	216168-33-1P	216168-34-2P	216168-35-3P	
<b>216168-36-4P</b>	216168-37-5P	216168-38-6P	216168-39-7P	
216168-40-0P	216168-41-1P	216168-42-2P	216168-43-3P	216168-44-4P
216168-45-5P	216168-46-6P	216168-47-7P	216168-48-8P	

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of phenolic compds. for the inhibition of the expression of VCAM-1)

IT 74-79-3, L-Arginine, reactions 100-11-8, 4-Nitrobenzyl bromide 104-81-4, 4-Methylbenzyl bromide 108-30-5, Succinic anhydride, reactions 108-55-4, Glutaric anhydride 402-49-3, 4-Trifluoromethylbenzyl bromide 459-46-1, 4-Fluorobenzyl bromide 556-52-5, Oxiranemethanol 610-57-1, 2,4-Dinitrobenzyl chloride 619-23-8, 3-Nitrobenzyl chloride 623-47-2, Ethyl propiolate 623-48-3, Ethyl iodoacetate 1118-89-4, L-Glutamic acid diethyl ester hydrochloride 1464-53-5, 1,3-Butadiene diepoxide 1499-17-8, 1,2-Phenylene phosphochloridate 1501-26-4, Methyl 4-chloroformylbutyrate 2144-37-8, Methyl 5-chloromethyl-2-furoate 2478-10-6, 4-Hydroxybutyl acrylate 3145-86-6, 4-Nitrobenzyl iodide 3179-63-3 3446-91-1 4064-06-6, 1,2,3,4-Di-O-isopropylidene-D-galactopyranose 5394-18-3, N-(4-Bromobutyl)phthalimide 5407-04-5 6780-38-7 13100-46-4, 1,2,3,4-Tetra-O-acetyl-.beta.-D-glucopyranose 13737-36-5 14273-85-9, Methyl 4-iodobutyrate 15433-79-1, 5-(Dimethylaminomethyl)-2-furanmethanol 15445-34-8, Lysine methyl ester hydrochloride 17347-61-4, 2,2-Dimethylsuccinic anhydride 18997-19-8, Chloromethyl pivalate 20264-96-4 20395-28-2, 5-Chloropentyl acetate 23288-49-5, Probucol 25084-14-4, 5-Nitro-2-furoyl chloride 39720-27-9, 4-Chloromethylphenyl acetate 50438-75-0, Benzeneethanol, 4-Dimethylamino- 73384-82-4, 3-Bromo-1-propanesulfonic acid 216168-64-8 216168-65-9

RL: RCT (Reactant); RACT (Reactant or reagent)

(prepn. of phenolic compds. for the inhibition of the expression of VCAM-1)

IT	950-59-4P	216168-49-9P	216168-52-4P	216168-53-5P	216168-54-6P
	216168-55-7P	216168-57-9P	216168-58-0P	216168-59-1P	216168-60-4P
	216168-61-5P	216168-62-6P	216168-63-7P	216168-66-0P	

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. of phenolic compds. for the inhibition of the expression of VCAM-1)

=> file reg

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	21.45	232.68
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-2.60	-3.25

FILE 'REGISTRY' ENTERED AT 11:22:09 ON 25 MAY 2003

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file

provided by InfoChem.

STRUCTURE FILE UPDATES: 23 MAY 2003 HIGHEST RN 519387-75-8  
DICTIONARY FILE UPDATES: 23 MAY 2003 HIGHEST RN 519387-75-8

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2003

Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.


Experimental and calculated property data are now available. See HELP  
PROPERTIES for more information. See STNote 27, Searching Properties  
in the CAS Registry File, for complete details:

<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=> s l3 and C36 H58 O4 S2/mf  
9 C36 H58 O4 S2/MF  
L13 1 L3 AND C36 H58 O4 S2/MF

=> d

L13 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2003 ACS  
RN 216168-02-4 REGISTRY  
CN Phenol, 4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-(3-ethoxy-2-  
hydroxypropoxy)phenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)-  
(9CI) (CA INDEX NAME)  
FS 3D CONCORD  
MF **C36 H58 O4 S2**  
SR CA  
LC STN Files: CA, CAPLUS, USPATFULL



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1957 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1957 TO DATE)

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
7.50	240.18

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
0.00	-3.25

CA SUBSCRIBER PRICE

FILE 'CAPLUS' ENTERED AT 11:24:33 ON 25 MAY 2003

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 25 May 2003 VOL 138 ISS 22  
FILE LAST UPDATED: 23 May 2003 (20030523/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l13

L14 1 L13

=> d ibib abs hitstr

L14 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1998:761875 CAPLUS

DOCUMENT NUMBER: 130:13646

TITLE: Preparation of phenolic compounds for the inhibition of the expression of VCAM-1

INVENTOR(S): Medford, Russell M.; Somers, Patricia K.; Hoong, Lee K.; Meng, Charles Q.

PATENT ASSIGNEE(S): Atherogenics, Inc., USA

SOURCE: PCT Int. Appl., 109 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 4

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9851662	A2	19981119	WO 1998-US9781	19980514
WO 9851662	A3	20000302		
W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
AU 9874851	A1	19981208	AU 1998-74851	19980514
AU 750041	B2	20020711		
EP 994853	A2	20000426	EP 1998-922264	19980514
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
US 6121319	A	20000919	US 1998-78935	19980514
BR 9809819	A	20010918	BR 1998-9819	19980514
JP 2002503227	T2	20020129	JP 1998-549502	19980514
NO 9905544	A	20000110	NO 1999-5544	19991112
MX 9910402	A	20000630	MX 1999-10402	19991112

PRIORITY APPLN. INFO.:


US 1997-47020P P 19970514

WO 1998-US9781 W 19980514

OTHER SOURCE(S):

MARPAT 130:13646

GI



AB Title compds. [e.g., I; R = Z1Z2R5; R1,R2 = (un)substituted (cyclo)alkyl, -(hetero)aryl, etc.; R3,R4 = any group that does not otherwise adversely affect (sic) the desired properties of the mol. including H, halogen, or R1 (sic); R5 = (di)(alkyl)amino, alkyl, alkoxy(carbonyl), (hetero)aryl, etc.; Z1 = O SOO-2, NH, CH2; Z2 = bond, alkylene(oxy) aryleneoxy, etc.] were prepd. Thus, 4-(BrCH2)C6H4CH2CO2H was thioetherified by 4-mercapto-2,6-di-tert-butylphenol to give I [R = SCH2C6H4(CH2CO2H)-4, R1 = R2 = CMe3, R3 = R4 = H]. Data for biol. activity of I were given.


IT 216168-02-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of phenolic compds. for the inhibition of the expression of VCAM-1)

RN 216168-02-4 CAPLUS

CN Phenol, 4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-(3-ethoxy-2-hydroxypropoxy)phenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)-(9CI) (CA INDEX NAME)



=> s 13 and C35 H54 O4 S2/mf

#### REGISTRY INITIATED

Substance data SEARCH and crossover from CAS REGISTRY in progress...

Use DISPLAY HITSTR (or FHITSTR) to directly view retrieved structures.

14 L3  
L17 5 L3 AND L16

=> d ibib abs hitstr 1-5 it

L17 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2002:849415 CAPLUS

DOCUMENT NUMBER: 137:333157

TITLE: Probucol monoesters for increasing levels and  
improving functionality of plasma HDL cholesterol  
INVENTOR(S): Luchoomun, Jayraz; Saxena, Uday; Sundell, Cynthia L.;  
Sikorski, James A.

PATENT ASSIGNEE(S): Atherogenics, Inc., USA

SOURCE: PCT Int. Appl., 161 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002087556	A2	20021107	WO 2002-US12678	20020411
WO 2002087556	A3	20030206		
WO 2002087556	C2	20030320		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,  
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,  
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,  
PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,  
UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU,  
TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,  
CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,  
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2003064967 A1 20030403 US 2002-122516 20020411

PRIORITY APPLN. INFO.: US 2001-283376P P 20010411

US 2001-345025P P 20011109

OTHER SOURCE(S): MARPAT 137:333157

AB It has been discovered that certain selected probucol monoesters, and  
their pharmaceutically acceptable salts or prodrugs, are useful for  
increasing circulating HDL cholesterol. These compds. may also improve  
HDL functionality by (a) increasing clearance of cholesteryl esters, (b)  
increasing HDL-particle affinity for hepatic cell surface receptors, or  
(c) increasing the half-life of apoAI-HDL. The pharmaceutical compns.  
comprise probucol monoesters alone or in combination with other agents,  
e.g, statins, IBAT inhibitors, MTP inhibitors, cholesterol absorption  
inhibitors, phytosterols, CETP inhibitors, fibric acid derivs., and  
antihypertensive agents. For example, mono[4-[[1-[[3,5-bis(1,1-  
dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-  
dimethylethyl)phenyl]ester of pentanedioic acid, prepd. from probucol and  
glutaric anhydride, elevated HDLc in hyperlipidemic hamster by 22% (av. of  
3 expts., range 5-44%), compared to untreated controls after 2 wk  
treatment at a dose of 150 mg/kg/day. LDLc was reduced by 29% on av.,  
VLDL cholesterol by 42%, and triglycerides by 24%, compared to controls.  
The compd. was well tolerated and all animals gained wt.


IT 216167-88-3

RL: RCT (Reactant); RACT (Reactant or reagent)

(prepn. of probucol monoesters for increasing levels and improving  
functionality of plasma HDL cholesterol)

RN 216167-88-3 CAPLUS

CN Butanoic acid, 4-hydroxy-, 4-[[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenyl ester (9CI) (CA INDEX NAME)




IT 216167-80-5P 216167-82-7P 216167-94-1P  
474236-49-2P 474236-50-5P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(prepn. of probucol monoesters for increasing levels and improving functionality of plasma HDL cholesterol)


RN 216167-80-5 CAPLUS

CN Pentanedioic acid, 4-[[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenyl methyl ester (9CI) (CA INDEX NAME)




RN 216167-82-7 CAPLUS

CN Butanedioic acid, mono[4-[[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenyl] ester (9CI) (CA INDEX NAME)




RN 216167-94-1 CAPLUS

CN Pentanedioic acid, mono[4-[[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenyl] ester (9CI) (CA INDEX NAME)



RN 474236-49-2 CAPLUS


CN Butanoic acid, 4-(sulfooxy)-, 1-[4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenyl] ester, monosodium salt (9CI) (CA INDEX NAME)



● Na

RN 474236-50-5 CAPLUS

CN Acetic acid, [2-[4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenoxy]-2-oxoethoxy]- (9CI) (CA INDEX NAME)



IT Apolipoproteins

RL: BSU (Biological study, unclassified); BIOL (Biological study) (A-I; prepn. of probucol monoesters for increasing levels and improving functionality of plasma HDL cholesterol)

IT Gene, animal

RL: BSU (Biological study, unclassified); BIOL (Biological study) (APOAI; prepn. of probucol monoesters for increasing levels and improving functionality of plasma HDL cholesterol and evaluation in animals transfected with human apo-AI gene)

IT Ion channel blockers

(calcium; compns. contg. probucol monoesters for increasing levels and improving functionality of plasma HDL cholesterol in combination with other drugs)

IT Drug delivery systems

(compns. contg. probucol monoesters for increasing levels and improving functionality of plasma HDL cholesterol alone or in combination with

other drugs)

IT Antihypertensives  
Diuretics  
Vasodilators  
(comps. contg. probucol monoesters for increasing levels and improving functionality of plasma HDL cholesterol in combination with other drugs)

IT Lipoproteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(high-d., HDLc; prepn. of probucol monoesters for increasing levels and improving functionality of plasma HDL cholesterol)

IT Lipoproteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(high-d.; prepn. of probucol monoesters for increasing levels and improving functionality of plasma HDL cholesterol)

IT Hamster  
(prepn. and evaluation in hamster of probucol monoesters for increasing levels and improving functionality of plasma HDL cholesterol)

IT Mouse  
(prepn. and evaluation in mouse of probucol monoesters for increasing levels and improving functionality of plasma HDL cholesterol)

IT Anticholesteremic agents  
(prepn. of probucol monoesters for increasing levels and improving functionality of plasma HDL cholesterol)

IT Human  
(prepn. of probucol monoesters for increasing levels and improving functionality of plasma HDL cholesterol and evaluation in animals transfected with human apo-AI gene)

IT 108-30-5, Succinic anhydride, reactions 108-55-4, Glutaric anhydride 1501-26-4 3162-58-1, Sulfur trioxide trimethylamine 4480-83-5, Diglycolic anhydride 23288-49-5, Probucol **216167-88-3**  
RL: RCT (Reactant); RACT (Reactant or reagent)  
(prepn. of probucol monoesters for increasing levels and improving functionality of plasma HDL cholesterol)

IT **216167-80-5P 216167-82-7P 216167-94-1P 474236-49-2P 474236-50-5P**  
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(prepn. of probucol monoesters for increasing levels and improving functionality of plasma HDL cholesterol)

L17 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2002:814837 CAPLUS

DOCUMENT NUMBER: 137:320305

TITLE: Probucol derivatives and methods for treating transplant rejection

INVENTOR(S): Edwards, David B.; Somers, Patricia K.; Glass, Mitchell

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 22 pp., Cont.-in-part of U.S. Ser. No. 815,262.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 4

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002156022	A1	20021024	US 2001-36307	20011025
US 6147250	A	20001114	US 1998-79213	19980514
US 6548699	B1	20030415	US 1999-370046	19990806




US 2002016300	A1	20020207	US 2001-815262	20010321
US 2002177717	A1	20021128	US 2002-60734	20020130
US 2002169215	A1	20021114	US 2002-114346	20020402
US 2002188118	A1	20021212	US 2002-115206	20020402
US 2002193446	A1	20021219	US 2002-114351	20020402

PRIORITY APPLN. INFO.:

US 1997-47020P	P	19970514
US 1998-79213	A1	19980514
US 1999-370046	A2	19990806
US 2000-191046P	P	20000321
US 2001-815262	A2	20010321

OTHER SOURCE(S): MARPAT 137:320305  
GI



AB The invention discloses the use of I [R1-R4 = H, OH, C1-10 alkyl, aryl, heteroaryl, etc.; Y = bond, C(O); Z = C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, etc.], and pharmaceutically acceptable salts thereof, alone or in combination, for the treatment of transplant rejection. Prepn. of I [R1-R4 = tert-butyl; YZ = (CH2)3COOH] from probucol which was evaluated in a graft arteriopathy model and Me 4-chlorobutyrate is described.


IT **216167-95-2P**

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(probucol derivs. for treatment of transplant rejection)

RN 216167-95-2 CAPLUS

CN Butanoic acid, 4-[4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenoxy]- (9CI) (CA INDEX NAME)




IT **216167-82-7 216167-86-1 216167-92-9**  
**216167-93-0 216167-94-1 216168-01-3**  
**216168-28-4 216168-36-4 366494-64-6**  
**473427-26-8 473427-29-1**

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(probucol derivs. for treatment of transplant rejection)


RN 216167-82-7 CAPLUS

CN Butanedioic acid, mono[4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenyl] ester (9CI) (CA INDEX NAME)




RN 216167-86-1 CAPLUS

CN Phenol, 4-[[1-[[4-(4-aminobutoxy)-3,5-bis(1,1-dimethylethyl)phenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)




RN 216167-92-9 CAPLUS

CN    Acetic acid, [4-[[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenoxy]- (9CI)    (CA INDEX NAME)



RN 216167-93-0 CAPLUS


CN Glycine, 4-[[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenyl ester (9CI) (CA INDEX NAME)



RN 216167-94-1 CAPLUS


CN Pentanedioic acid, mono[4-[[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenyl]

ester (9CI) (CA INDEX NAME)



RN 216168-01-3 CAPLUS


CN 1,2,3-Butanetriol, 4-[4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenoxy]- (9CI) (CA INDEX NAME)



RN 216168-28-4 CAPLUS

CN L-Glutamic acid, N-[3-[4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenoxy]-2-hydroxypropyl]-, diethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 216168-36-4 CAPLUS


CN D-Glucitol, 6-O-[4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 366494-64-6 CAPLUS  
 CN D-Ribonic acid, 5-O-[4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenyl]-, .gamma.-lactone (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 473427-26-8 CAPLUS  
 CN Hexitol, 6-O-[4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 473427-29-1 CAPLUS  
 CN .alpha.-D-Glucopyranose, 6-O-[4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT Transplant and Transplantation  
 (allotransplant, aorta; probucol derivs. for treatment of transplant rejection)  
 IT Artery  
 (aorta, allotransplant; probucol derivs. for treatment of transplant rejection)  
 IT Arteriosclerosis

Cell proliferation  
Cytotoxic agents  
Immunosuppressants  
Transplant and Transplantation  
Transplant rejection

(probucol derivs. for treatment of transplant rejection)

IT Steroids, biological studies

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
(Biological study); USES (Uses)

(probucol derivs. for treatment of transplant rejection)

IT Blood vessel

(smooth muscle; probucol derivs. for treatment of transplant rejection)

IT **216167-95-2P**

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic  
preparation); THU (Therapeutic use); BIOL (Biological study); PREP  
(Preparation); RACT (Reactant or reagent); USES (Uses)

(probucol derivs. for treatment of transplant rejection)

IT 59-05-2, Methotrexate 446-86-6, Azathioprine 24280-93-1, Mycophenolic  
acid 53123-88-9, Sirolimus 79217-60-0, Cyclosporin 104987-11-3,  
Tacrolimus 128794-94-5, Mycophenolate mofetil 159351-69-6, Everolimus

**216167-82-7 216167-86-1 216167-92-9**

**216167-93-0 216167-94-1 216168-01-3**

**216168-28-4 216168-36-4** 260370-57-8, NOX-100

**366494-64-6 473427-26-8 473427-29-1**

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
(Biological study); USES (Uses)

(probucol derivs. for treatment of transplant rejection)

IT 3153-37-5, Methyl 4-chlorobutyrate 23288-49-5, Probucol

RL: RCT (Reactant); RACT (Reactant or reagent)

(reaction; probucol derivs. for treatment of transplant rejection)

L17 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2002:641096 CAPLUS

DOCUMENT NUMBER: 138:313884

TITLE: Novel phenolic antioxidants as multifunctional  
inhibitors of inducible VCAM-1 expression for use in  
atherosclerosis

AUTHOR(S): Meng, Charles Q.; Somers, Patricia K.; Rachita,  
Carolyn L.; Holt, Lisa A.; Hoong, Lee K.; Zheng, X.  
Sharon; Simpson, Jacob E.; Hill, Russell R.; Olliff,  
Lynda K.; Kunsch, Charles; Sundell, Cynthia L.;  
Parthasarathy, Sampath; Saxena, Uday; Sikorski, James  
A.; Wasserman, Martin A.

CORPORATE SOURCE: AtheroGenics, Inc., Alpharetta, GA, 30004, USA

SOURCE: Bioorganic & Medicinal Chemistry Letters (2002),  
12(18), 2545-2548

CODEN: BMCLE8; ISSN: 0960-894X

PUBLISHER: Elsevier Science Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB A series of novel phenolic compds. has been discovered as potent  
inhibitors of TNF- $\alpha$ -inducible expression of vascular cell adhesion  
mol.-1 (VCAM-1) with concurrent antioxidant and lipid-modulating  
properties. Optimization of these multifunctional agents led to the  
identification of AGI-1067 as a clin. candidate with demonstrated  
efficacies in animal models of atherosclerosis and hyperlipidemia.

IT **216167-82-7, AGI-1067 216167-88-3 216167-94-1**

**216168-38-6 216168-43-3 219773-27-0**

**474236-50-5 512790-96-4 512790-97-5**

**512790-98-6 512790-99-7 512791-00-3**

**512791-01-4 512791-02-5 512791-03-6**


**512791-04-7**

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
(Biological study); USES (Uses)

(phenolic antioxidants as inhibitors of inducible VCAM-1 expression for  
use in atherosclerosis)


RN 216167-82-7 CAPLUS

CN Butanedioic acid, mono[4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-  
hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenyl]  
ester (9CI) (CA INDEX NAME)




RN 216167-88-3 CAPLUS

CN Butanoic acid, 4-hydroxy-, 4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-  
hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenyl  
ester (9CI) (CA INDEX NAME)




RN 216167-94-1 CAPLUS

CN Pentanedioic acid, mono[4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-  
hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenyl]  
ester (9CI) (CA INDEX NAME)




RN 216168-38-6 CAPLUS

CN Butanoic acid, 4-hydroxy-3,3-dimethyl-, 4-[[1-[[3,5-bis(1,1-dimethylethyl)-  
4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenyl  
ester (9CI) (CA INDEX NAME)




RN 216168-43-3 CAPLUS

CN Butanedioic acid, 4-[[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenyl methyl ester (9CI)  
(CA INDEX NAME)




RN 219773-27-0 CAPLUS

CN Octanedioic acid, mono[4-[[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenyl] ester (9CI) (CA INDEX NAME)




RN 474236-50-5 CAPLUS

CN Acetic acid, [2-[4-[[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenoxy]-2-oxoethoxy]- (9CI)  
(CA INDEX NAME)



RN 512790-96-4 CAPLUS


CN Ethanedioic acid, mono[4-[[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenyl] ester (9CI) (CA INDEX NAME)



RN 512790-97-5 CAPLUS


CN D-Aspartic acid, N-(phenylacetyl)-, 4-[4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenyl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 512790-98-6 CAPLUS

CN 2-Butenedioic acid, 2-(acetyloxy)-, 4-[4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenyl] ester (9CI) (CA INDEX NAME)




RN 512790-99-7 CAPLUS

CN Pentanedioic acid, 2-hydroxy-, 1-[4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenyl] ester, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.






RN 512791-00-3 CAPLUS

CN Pentanedioic acid, hexafluoro-, mono[4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenyl] ester (9CI) (CA INDEX NAME)




RN 512791-01-4 CAPLUS

CN Acetic acid, hydroxy-, 4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenyl ester (9CI) (CA INDEX NAME)




RN 512791-02-5 CAPLUS

CN Propanoic acid, 3-hydroxy-, 4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenyl ester (9CI) (CA INDEX NAME)




RN 512791-03-6 CAPLUS

CN Pentanoic acid, 5-hydroxy-, 4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenyl ester (9CI) (CA INDEX NAME)



RN 512791-04-7 CAPLUS

CN Butanoic acid, 3,4-dihydroxy-, 4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenyl ester (9CI) (CA INDEX NAME)



IT Cell adhesion molecules

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(VCAM-1; phenolic antioxidants as inhibitors of inducible VCAM-1 expression for use in atherosclerosis)

IT Antiarteriosclerotics

(antiatherosclerotics; phenolic antioxidants as inhibitors of inducible VCAM-1 expression for use in atherosclerosis)

IT Lipids, biological studies

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(hyperlipidemia; phenolic antioxidants as inhibitors of inducible VCAM-1 expression for use in atherosclerosis)

IT Atherosclerosis

Structure-activity relationship

(phenolic antioxidants as inhibitors of inducible VCAM-1 expression for use in atherosclerosis)

IT Antioxidants

(phenolic; phenolic antioxidants as inhibitors of inducible VCAM-1 expression for use in atherosclerosis)

IT 216167-82-7, AGI-1067 216167-88-3 216167-94-1

216168-38-6 216168-43-3 219773-27-0

474236-50-5 512790-96-4 512790-97-5

512790-98-6 512790-99-7 512791-00-3

512791-01-4 512791-02-5 512791-03-6

512791-04-7

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
(Biological study); USES (Uses)

(phenolic antioxidants as inhibitors of inducible VCAM-1 expression for use in atherosclerosis)


REFERENCE COUNT:

33

THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


ACCESSION NUMBER: 2000:335659 CAPLUS  
 DOCUMENT NUMBER: 132:343330  
 TITLE: Methods and compositions to lower plasma cholesterol levels  
 INVENTOR(S): Medford, Russell M.; Saxena, Uday  
 PATENT ASSIGNEE(S): Atherogenics, Inc., USA  
 SOURCE: PCT Int. Appl., 50 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000028332	A1	20000518	WO 1999-US26519	19991109
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1137948	A1	20011004	EP 1999-962732	19991109
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002529740	T2	20020910	JP 2000-581459	19991109
PRIORITY APPLN. INFO.: US 1998-107644P P 19981109 WO 1999-US26519 W 19991109				
AB	A method for detg. whether a compd. binds to a lipoprotein, e.g. LDL or VLDL, in a manner which will lower plasma cholesterol is provided that includes assessing the ability of the compd. to form a complex with the lipoprotein, e.g., LDL or VLDL, and then detg. whether the newly formed complex causes a change in the structure of apoB-100 that results in increased binding affinity to the LDL receptor. Also disclosed is a method for lowering cholesterol in a host in need thereof, including a human, that includes the administration of an effective amt. of a compd. which binds to cholesterol-carrying lipoprotein (e.g. LDL or VLDL) in a manner that alters the three dimensional configuration of the lipoprotein and increases the binding affinity of the apoB-100 protein to the LDL receptor, including those on the surface of a hepatic cell.			
IT	216167-82-7 216167-84-9 216167-91-8 216167-93-0 216167-94-1 216167-95-2 216168-35-3 216168-36-4 216168-42-2 268738-49-4 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (methods and compns. to lower plasma cholesterol levels)			
RN	216167-82-7 CAPLUS			
CN	Butanedioic acid, mono[4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenyl] ester (9CI) (CA INDEX NAME)			




RN 216167-84-9 CAPLUS

CN Butanoic acid, 4-[4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-dimethylphenoxy]- (9CI) (CA INDEX NAME)




RN 216167-91-8 CAPLUS

CN Butanoic acid, 4-[4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]phenoxy]- (9CI) (CA INDEX NAME)




RN 216167-93-0 CAPLUS

CN Glycine, 4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenyl ester (9CI) (CA INDEX NAME)




RN 216167-94-1 CAPLUS

CN Pentanedioic acid, mono[4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenyl] ester (9CI) (CA INDEX NAME)



RN 216167-95-2 CAPLUS


CN Butanoic acid, 4-[4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenoxy]- (9CI) (CA INDEX NAME)



RN 216168-35-3 CAPLUS

CN D-Glucose, 6-O-[4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 216168-36-4 CAPLUS

CN D-Glucitol, 6-O-[4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 216168-42-2 CAPLUS


CN Butanedioic acid, mono[4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-

hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-dimethylphenyl] ester (9CI)  
(CA INDEX NAME)



RN 268738-49-4 CAPLUS

CN Pentonic acid, 5-O-[4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenyl]- (9CI) (CA INDEX NAME)



IT Apolipoproteins

RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)  
(B-100; methods and compns. to lower plasma cholesterol levels)

IT Animal cell line

(Hep G2; methods and compns. to lower plasma cholesterol levels)

IT Liver

(LDL receptor of; methods and compns. to lower plasma cholesterol levels)

IT Lipoprotein receptors

RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)  
(LDL; methods and compns. to lower plasma cholesterol levels)

IT Electrophoresis

(agarose; methods and compns. to lower plasma cholesterol levels)

IT Phenotypes

(apoB-100; methods and compns. to lower plasma cholesterol levels)

IT Sequestering agents

(bile acid; methods and compns. to lower plasma cholesterol levels)

IT Immunoassay

(enzyme-linked immunosorbent assay, sandwich; methods and compns. to lower plasma cholesterol levels)

IT Lipoproteins

RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)  
(high-d.; methods and compns. to lower plasma cholesterol levels)

IT Lipoproteins

RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)  
(intermediate-d.; methods and compns. to lower plasma cholesterol levels)

IT Lipoproteins

RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)  
 (low-d.; methods and compns. to lower plasma cholesterol levels)

IT Anticholesteremic agents  
 Drug screening  
 Epitopes  
 Molecular association  
 (methods and compns. to lower plasma cholesterol levels)

IT Antibodies  
 RL: ARG (Analytical reagent use); ANST (Analytical study); USES (Uses)  
 (monoclonal; methods and compns. to lower plasma cholesterol levels)

IT Conformation  
 (protein; methods and compns. to lower plasma cholesterol levels)

IT Immunoassay  
 (sandwich; methods and compns. to lower plasma cholesterol levels)

IT Bile acids  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (sequestrants; methods and compns. to lower plasma cholesterol levels)

IT Drugs  
 (statins; methods and compns. to lower plasma cholesterol levels)

IT Antibodies  
 RL: ARG (Analytical reagent use); ANST (Analytical study); USES (Uses)  
 (to apoB-100; methods and compns. to lower plasma cholesterol levels)

IT Biological transport  
 (uptake, LDL; methods and compns. to lower plasma cholesterol levels)

IT Lipoproteins  
 RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)  
 (very-low-d.; methods and compns. to lower plasma cholesterol levels)

IT 9012-36-6, Agarose  
 RL: ARU (Analytical role, unclassified); ANST (Analytical study)  
 (electrophoresis; methods and compns. to lower plasma cholesterol levels)

IT 59-67-6, Nicotinic acid, biological studies 943-45-3D, Fibric acid, derivs. 1404-04-2, Neomycin 11041-12-6, Cholestyramine 23288-49-5, Probucol 25769-03-3, 1-Pyrrolidinecarbodithioic acid 216167-66-7 216167-67-8 216167-69-0 216167-74-7 **216167-82-7** **216167-84-9** **216167-91-8** **216167-93-0** **216167-94-1** **216167-95-2** **216168-35-3** **216168-36-4** **216168-42-2** 216168-49-9 268738-42-7 268738-43-8 268738-44-9 268738-45-0 268738-46-1 268738-47-2 268738-48-3 **268738-49-4** 268738-50-7 268738-51-8 268738-52-9 268738-53-0 268738-54-1  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (methods and compns. to lower plasma cholesterol levels)

IT 57-88-5, Cholesterol, biological studies  
 RL: BOC (Biological occurrence); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); OCCU (Occurrence); PROC (Process)  
 (methods and compns. to lower plasma cholesterol levels)

REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1998:761875 CAPLUS


DOCUMENT NUMBER: 130:13646

TITLE: Preparation of phenolic compounds for the inhibition of the expression of VCAM-1

INVENTOR(S): Medford, Russell M.; Somers, Patricia K.; Hoong, Lee K.; Meng, Charles Q.

PATENT ASSIGNEE(S): Atherogenics, Inc., USA  
 SOURCE: PCT Int. Appl., 109 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 4  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9851662	A2	19981119	WO 1998-US9781	19980514
WO 9851662	A3	20000302		
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9874851	A1	19981208	AU 1998-74851	19980514
AU 750041	B2	20020711		
EP 994853	A2	20000426	EP 1998-922264	19980514
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
US 6121319	A	20000919	US 1998-78935	19980514
BR 9809819	A	20010918	BR 1998-9819	19980514
JP 2002503227	T2	20020129	JP 1998-549502	19980514
NO 9905544	A	20000110	NO 1999-5544	19991112
MX 9910402	A	20000630	MX 1999-10402	19991112
PRIORITY APPLN. INFO.:			US 1997-47020B	P 19970514
			WO 1998-US9781	W 19980514
OTHER SOURCE(S):			MARPAT 130:13646	
GI				



AB Title compds. [e.g., I; R = Z1Z2R5; R1,R2 = (un)substituted (cyclo)alkyl, -(hetero)aryl, etc.; R3,R4 = any group that does not otherwise adversely affect (sic) the desired properties of the mol. including H, halogen, or R1 (sic); R5 = (di)(alkyl)amino, alkyl, alkoxy(carbonyl), (hetero)aryl, etc.; Z1 = O SOO-2, NH, CH2; Z2 = bond, alkylene(oxy) aryleneoxy, etc.] were prepd. Thus, 4-(BrCH2)C6H4CH2CO2H was thioetherified by 4-mercapto-2,6-di-tert-butylphenol to give I [R = SCH2C6H4(CH2CO2H)-4, R1 = R2 = CMe3, R3 = R4 = H]. Data for biol. activity of I were given.

IT 216167-80-5P 216167-81-6P 216167-82-7P  
 216167-83-8P 216167-84-9P 216167-85-0P  
 216167-86-1P 216167-88-3P 216167-89-4P  
 216167-90-7P 216167-91-8P 216167-92-9P  
 216167-93-0P 216167-94-1P 216167-95-2P  
 216167-96-3P 216167-97-4P 216167-98-5P  
 216167-99-6P 216168-00-2P 216168-01-3P




216168-02-4P 216168-03-5P 216168-05-7P  
 216168-07-9P 216168-14-8P 216168-18-2P  
 216168-20-6P 216168-22-8P 216168-24-0P  
 216168-26-2P 216168-27-3P 216168-28-4P  
 216168-29-5P 216168-30-8P 216168-31-9P  
 216168-32-0P 216168-33-1P 216168-34-2P  
 216168-35-3P 216168-36-4P 216168-37-5P  
 216168-38-6P 216168-39-7P 216168-41-1P  
 216168-42-2P 216168-43-3P 216168-44-4P  
 216168-47-7P 216168-48-8P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (prepn. of phenolic compds. for the inhibition of the expression of VCAM-1)


RN 216167-80-5 CAPLUS

CN Pentanedioic acid, 4-[[[1-[[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenyl methyl ester (9CI) (CA INDEX NAME)




RN 216167-81-6 CAPLUS


CN Phenol, 4-[[[1-[[[3,5-bis(1,1-dimethylethyl)-4-[(4-nitrophenyl)methoxy]phenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)



RN 216167-82-7 CAPLUS


CN Butanedioic acid, mono[4-[[[1-[[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenyl] ester (9CI) (CA INDEX NAME)






RN 216167-83-8 CAPLUS

CN 2-Furancarboxylic acid, 5-nitro-, 4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenyl ester (9CI) (CA INDEX NAME)




RN 216167-84-9 CAPLUS

CN Butanoic acid, 4-[[4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-dimethylphenoxy]-5-nitrofuran-2-yl ester (9CI) (CA INDEX NAME)




RN 216167-85-0 CAPLUS

CN Phenol, 4-[[1-[[4-(4-aminobutoxy)-3,5-dimethylphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenyl ester (9CI) (CA INDEX NAME)




RN 216167-86-1 CAPLUS

CN Phenol, 4-[[1-[[4-(4-aminobutoxy)-3,5-bis(1,1-dimethylethyl)phenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenyl ester (9CI) (CA INDEX NAME)




RN 216167-88-3 CAPLUS

CN Butanoic acid, 4-hydroxy-, 4-[[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenyl ester (9CI) (CA INDEX NAME)




RN 216167-89-4 CAPLUS

CN 2-Butanone, 1-[4-[[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenoxy]-3,3-dimethyl- (9CI) (CA INDEX NAME)




RN 216167-90-7 CAPLUS

CN Phenol, 4-[[[1-[[4-(4-aminobutoxy)phenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)




RN 216167-91-8 CAPLUS

CN Butanoic acid, 4-[4-[[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]phenoxy]- (9CI) (CA INDEX NAME)




RN 216167-92-9 CAPLUS

CN Acetic acid, [4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenoxy]- (9CI) (CA INDEX NAME)




RN 216167-93-0 CAPLUS

CN Glycine, 4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenyl ester (9CI) (CA INDEX NAME)



RN 216167-94-1 CAPLUS


CN Pentanedioic acid, mono[4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenyl] ester (9CI) (CA INDEX NAME)



RN 216167-95-2 CAPLUS


CN Butanoic acid, 4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenoxy]- (9CI) (CA INDEX NAME)

NAME)




RN 216167-96-3 CAPLUS

CN Oxiranemethanol, .alpha.-[[4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenoxy]methyl]- (9CI) (CA INDEX NAME)




RN 216167-97-4 CAPLUS

CN Oxiranemethanol, 3-[[4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenoxy]methyl]- (9CI) (CA INDEX NAME)




RN 216167-98-5 CAPLUS

CN Oxiranemethanol, .alpha.-[[[3-[[4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenoxy]methyl]oxiranyl]methoxy]methyl]- (9CI) (CA INDEX NAME)




RN 216167-99-6 CAPLUS

CN Phenol, 4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-(oxiranylmethoxy)phenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)




RN 216168-00-2 CAPLUS

CN Glycine, N-[3-[4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenoxy]-2-hydroxypropyl]- (9CI) (CA INDEX NAME)




RN 216168-01-3 CAPLUS

CN 1,2,3-Butanetriol, 4-[4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenoxy]- (9CI) (CA INDEX NAME)




RN 216168-02-4 CAPLUS

CN Phenol, 4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-(3-ethoxy-2-hydroxypropoxy)phenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)-  
(9CI) (CA INDEX NAME)




RN 216168-03-5 CAPLUS

CN 1,2-Propanediol, 3-[4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenoxy]-  
(9CI) (CA INDEX NAME)



RN 216168-05-7 CAPLUS


CN Phenol, 4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-ethoxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)




RN 216168-07-9 CAPLUS

CN 2-Propenoic acid, 3-[4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenoxy]-  
, ethyl ester, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 216168-14-8 CAPLUS  
 CN Phenol, 4-[[1-[[4-[2-[4-(dimethylamino)phenyl]ethoxy]-3,5-bis(1,1-dimethylethyl)phenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)-(9CI) (CA INDEX NAME)



RN 216168-18-2 CAPLUS  
 CN L-Arginine, N2-[4-[4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenoxy]-1,4-dioxobutyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

NH2

RN 216168-20-6 CAPLUS  
 CN 2-Propenoic acid, 3-[4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenoxy]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown..






RN 216168-22-8 CAPLUS


CN .alpha.-D-Galactopyranose, 6-O-[4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenyl]-1,2:3,4-bis-O-(1-methylethylidene)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 216168-24-0 CAPLUS

CN Phenol, 4-[[1-[[4-[3-(dimethylamino)propoxy]-3,5-bis(1,1-dimethylethyl)phenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)



RN 216168-26-2 CAPLUS


CN Glycine, N-[[4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenoxy]acetyl]- (9CI) (CA INDEX NAME)



RN 216168-27-3 CAPLUS

CN L-Glutamic acid, N-[[4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenoxy]acetyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 216168-28-4 CAPLUS


CN L-Glutamic acid, N-[3-[4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenoxy]-2-hydroxypropyl]-, diethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 216168-29-5 CAPLUS

CN 2-Propenoic acid, 4-[4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenoxy]butyl ester (9CI) (CA INDEX NAME)



RN 216168-30-8 CAPLUS


CN Phenol, 4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-(4-hydroxybutoxy)phenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)



RN 216168-31-9 CAPLUS


CN .beta.-D-Glucopyranose, 6-O-[4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenyl]-, 1,2,3,4-tetraacetate (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 216168-32-0 CAPLUS


CN 1H-Tetrazole-1-butanoic acid, 4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenyl ester (9CI) (CA INDEX NAME)




RN 216168-33-1 CAPLUS

CN Phenol, 4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-[[1E)-3-hydroxy-1-propenyl]oxy]phenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.






RN 216168-34-2 CAPLUS

CN L-Lysine, N2-[[4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenoxy]acetyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 216168-35-3 CAPLUS

CN D-Glucose, 6-O-[4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 216168-36-4 CAPLUS


CN D-Glucitol, 6-O-[4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 216168-37-5 CAPLUS

CN Butanoic acid, 4-[[hydroxy(2-hydroxyphenoxy)phosphinyl]oxy]-, 4-[[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenyl ester (9CI) (CA INDEX NAME)




RN 216168-38-6 CAPLUS

CN Butanoic acid, 4-hydroxy-3,3-dimethyl-, 4-[[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenyl ester (9CI) (CA INDEX NAME)




RN 216168-39-7 CAPLUS

CN Butanoic acid, 4-(sulfooxy)-, 1-[4-[[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenyl] ester (9CI) (CA INDEX NAME)




RN 216168-41-1 CAPLUS

CN Butanoic acid, 4-amino-4-oxo-, 4-[[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenyl ester (9CI) (CA INDEX NAME)




RN 216168-42-2 CAPLUS

CN Butanedioic acid, mono[4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-dimethylphenyl] ester (9CI) .  
(CA INDEX NAME)




RN 216168-43-3 CAPLUS

CN Butanedioic acid, 4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenyl methyl ester (9CI)  
(CA INDEX NAME)




RN 216168-44-4 CAPLUS

CN Pentanoic acid, 5-[4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenoxy]- (9CI) (CA INDEX NAME)



RN 216168-47-7 CAPLUS


CN Glycine, N-[4-[[4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenoxy]-2,3-dihydroxybutyl]- (9CI) (CA INDEX NAME)



RN 216168-48-8 CAPLUS

CN L-Lysine, N6-[3-[4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenoxy]-2-hydroxypropyl]- (9CI) (CA. INDEX NAME)

Absolute stereochemistry.



IT 216168-52-4P 216168-53-5P 216168-54-6P

216168-55-7P 216168-57-9P 216168-58-0P


216168-59-1P 216168-60-4P 216168-61-5P

216168-62-6P 216168-63-7P 216168-66-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(prepn. of phenolic compds. for the inhibition of the expression of VCAM-1)


RN 216168-52-4 CAPLUS

CN Butanoic acid, 4-[4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-dimethylphenoxy]-, methyl ester (9CI) (CA INDEX NAME)




RN 216168-53-5 CAPLUS


CN 1H-Isoindole-1,3(2H)-dione, 2-[4-[4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-dimethylphenoxy]butyl]- (9CI) (CA INDEX NAME)




RN 216168-54-6 CAPLUS  
 CN 1H-Isoindole-1,3(2H)-dione, 2-[4-[4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenoxy]butyl]- (9CI) (CA INDEX NAME)



RN 216168-55-7 CAPLUS  
 CN 1H-Isoindole-1,3(2H)-dione, 2-[4-[4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]phenoxy]butyl]- (9CI) (CA INDEX NAME)




RN 216168-57-9 CAPLUS  
 CN Acetic acid, [4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenoxy]-, ethyl ester (9CI) (CA INDEX NAME)






RN 216168-58-0 CAPLUS

CN 2H-Isoindole-2-acetic acid, 1,3-dihydro-1,3-dioxo-, 4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenyl ester (9CI) (CA INDEX NAME)




RN 216168-59-1 CAPLUS

CN Butanoic acid, 4-[4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenoxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 216168-60-4 CAPLUS


CN Glycine, N-[[4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenoxy]acetyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 216168-61-5 CAPLUS

CN L-Glutamic acid, N-[[4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenoxy]acetyl]-, diethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 216168-62-6 CAPLUS


CN L-Lysine, N2-[[4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenoxy]acetyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 216168-63-7 CAPLUS

CN Butanedioic acid, 2,2-dimethyl-, 4-[4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenyl] ester (9CI) (CA INDEX NAME)



RN 216168-66-0 CAPLUS

CN Butanoic acid, 4-[4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]phenoxy]-, methyl ester (9CI) (CA INDEX NAME)



IT Cell adhesion molecules

RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL

(Biological study); PROC (Process)

(VCAM-1, mediated disorders; treatment; prepn. of phenolic compds. for the inhibition of the expression of VCAM-1)

IT Anti-inflammatory agents

Cardiovascular agents

(prepn. of phenolic compds. for the inhibition of the expression of VCAM-1)

IT 54622-24-1P 123787-53-1P 141896-35-7P 216167-62-3P 216167-63-4P  
216167-64-5P 216167-65-6P 216167-66-7P 216167-67-8P 216167-68-9P  
216167-69-0P 216167-70-3P 216167-71-4P 216167-72-5P 216167-73-6P  
216167-74-7P 216167-75-8P 216167-76-9P 216167-77-0P 216167-78-1P  
216167-79-2P 216167-80-5P 216167-81-6P  
216167-82-7P 216167-83-8P 216167-84-9P  
216167-85-0P 216167-86-1P 216167-88-3P  
216167-89-4P 216167-90-7P 216167-91-8P  
216167-92-9P 216167-93-0P 216167-94-1P  
216167-95-2P 216167-96-3P 216167-97-4P  
216167-98-5P 216167-99-6P 216168-00-2P  
216168-01-3P 216168-02-4P 216168-03-5P  
216168-05-7P 216168-07-9P 216168-10-4P 216168-12-6P  
216168-14-8P 216168-16-0P 216168-18-2P  
216168-20-6P 216168-22-8P 216168-24-0P  
216168-26-2P 216168-27-3P 216168-28-4P  
216168-29-5P 216168-30-8P 216168-31-9P  
216168-32-0P 216168-33-1P 216168-34-2P  
216168-35-3P 216168-36-4P 216168-37-5P  
216168-38-6P 216168-39-7P 216168-40-0P  
216168-41-1P 216168-42-2P 216168-43-3P  
216168-44-4P 216168-45-5P 216168-46-6P 216168-47-7P  
216168-48-8P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of phenolic compds. for the inhibition of the expression of VCAM-1)

IT 74-79-3, L-Arginine, reactions 100-11-8, 4-Nitrobenzyl bromide  
104-81-4, 4-Methylbenzyl bromide 108-30-5, Succinic anhydride, reactions  
108-55-4, Glutaric anhydride 402-49-3, 4-Trifluoromethylbenzyl bromide  
459-46-1, 4-Fluorobenzyl bromide 556-52-5, Oxiranemethanol 610-57-1,  
2,4-Dinitrobenzyl chloride 619-23-8, 3-Nitrobenzyl chloride 623-47-2,  
Ethyl propiolate 623-48-3, Ethyl iodoacetate 1118-89-4, L-Glutamic  
acid diethyl ester hydrochloride 1464-53-5, 1,3-Butadiene diepoxide  
1499-17-8, 1,2-Phenylene phosphochloridate 1501-26-4, Methyl  
4-chloroformylbutyrate 2144-37-8, Methyl 5-chloromethyl-2-furoate  
2478-10-6, 4-Hydroxybutyl acrylate 3145-86-6, 4-Nitrobenzyl iodide  
3179-63-3 3446-91-1 4064-06-6, 1,2,3,4-Di-O-isopropylidene-D-  
galactopyranose 5394-18-3, N-(4-Bromobutyl)phthalimide 5407-04-5  
6780-38-7 13100-46-4, 1,2,3,4-Tetra-O-acetyl-.beta.-D-glucopyranose  
13737-36-5 14273-85-9, Methyl 4-iodobutyrate 15433-79-1,  
5-(Dimethylaminomethyl)-2-furanmethanol 15445-34-8, Lysine methyl ester  
hydrochloride 17347-61-4, 2,2-Dimethylsuccinic anhydride 18997-19-8,  
Chloromethyl pivalate 20264-96-4 20395-28-2, 5-Chloropentyl acetate  
23288-49-5, Probucol 25084-14-4, 5-Nitro-2-furoyl chloride 39720-27-9,  
4-Chloromethylphenyl acetate 50438-75-0, Benzeneethanol,  
4-Dimethylamino- 73384-82-4, 3-Bromo-1-propanesulfonic acid  
216168-64-8 216168-65-9

RL: RCT (Reactant); RACT (Reactant or reagent)

(prepn. of phenolic compds. for the inhibition of the expression of VCAM-1)

IT 950-59-4P 216168-49-9P 216168-52-4P 216168-53-5P  
216168-54-6P 216168-55-7P 216168-57-9P  
216168-58-0P 216168-59-1P 216168-60-4P


216168-61-5P 216168-62-6P 216168-63-7P

216168-66-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)

(prepn. of phenolic compds. for the inhibition of the expression of  
VCAM-1)


L18 ANSWER 2 OF 14 REGISTRY COPYRIGHT 2003 ACS  
 RN **216167-93-0** REGISTRY  
 CN Glycine, 4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenyl ester (9CI) (CA INDEX NAME)  
 FS 3D CONCORD  
 MF C33 H51 N O3 S2  
 SR CA  
 LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

3 REFERENCES IN FILE CA (1957 TO DATE)  
 3 REFERENCES IN FILE CAPLUS (1957 TO DATE)

L18 ANSWER 3 OF 14 REGISTRY COPYRIGHT 2003 ACS  
 RN **216167-92-9** REGISTRY  
 CN Acetic acid, [4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenoxy]- (9CI) (CA INDEX NAME)  
 FS 3D CONCORD  
 MF C33 H50 O4 S2  
 SR CA  
 LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

2 REFERENCES IN FILE CA (1957 TO DATE)  
 2 REFERENCES IN FILE CAPLUS (1957 TO DATE)

L18 ANSWER 4 OF 14 REGISTRY COPYRIGHT 2003 ACS  
 RN **216167-91-8** REGISTRY  
 CN Butanoic acid, 4-[4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]phenoxy]- (9CI) (CA INDEX NAME)  
 FS 3D CONCORD  
 MF C27 H38 O4 S2  
 SR CA


LC STN Files: CA, CAPLUS, USPATFULL



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

2 REFERENCES IN FILE CA (1957 TO DATE)  
2 REFERENCES IN FILE CAPLUS (1957 TO DATE)


L18 ANSWER 5 OF 14 REGISTRY COPYRIGHT 2003 ACS  
RN **216167-90-7** REGISTRY  
CN Phenol, 4-[[1-[[4-(4-aminobutoxy)phenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)  
FS 3D CONCORD  
MF C27 H41 N O2 S2  
SR CA  
LC STN Files: CA, CAPLUS, USPATFULL



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1957 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1957 TO DATE)


L18 ANSWER 6 OF 14 REGISTRY COPYRIGHT 2003 ACS  
RN **216167-89-4** REGISTRY  
CN 2-Butanone, 1-[4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenoxy]-3,3-dimethyl- (9CI) (CA INDEX NAME)  
FS 3D CONCORD  
MF C37 H58 O3 S2  
SR CA  
LC STN Files: CA, CAPLUS, USPATFULL



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1957 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1957 TO DATE)


L18 ANSWER 7 OF 14 REGISTRY COPYRIGHT 2003 ACS  
RN **216167-88-3** REGISTRY  
CN Butanoic acid, 4-hydroxy-, 4-[[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenyl ester (9CI) (CA INDEX NAME)  
FS 3D CONCORD  
MF C35 H54 O4 S2  
SR CA  
LC STN Files: CA, CAPLUS, USPATFULL



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

3 REFERENCES IN FILE CA (1957 TO DATE)  
3 REFERENCES IN FILE CAPLUS (1957 TO DATE)


L18 ANSWER 8 OF 14 REGISTRY COPYRIGHT 2003 ACS  
RN **216167-86-1** REGISTRY  
CN Phenol, 4-[[[1-[[4-(4-aminobutoxy)-3,5-bis(1,1-dimethylethyl)phenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)  
FS 3D CONCORD  
MF C35 H57 N O2 S2  
SR CA  
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

2 REFERENCES IN FILE CA (1957 TO DATE)  
2 REFERENCES IN FILE CAPLUS (1957 TO DATE)


L18 ANSWER 9 OF 14 REGISTRY COPYRIGHT 2003 ACS  
RN **216167-85-0** REGISTRY  
CN Phenol, 4-[[1-[[4-(4-aminobutoxy)-3,5-dimethylphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)  
FS 3D CONCORD  
MF C29 H45 N O2 S2  
SR CA  
LC STN Files: CA, CAPLUS, USPATFULL



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1957 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1957 TO DATE)

L18 ANSWER 10 OF 14 REGISTRY COPYRIGHT 2003 ACS  
RN **216167-84-9** REGISTRY  
CN Butanoic acid, 4-[4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-dimethylphenoxy]- (9CI) (CA INDEX NAME)  
FS 3D CONCORD  
MF C29 H42 O4 S2  
SR CA  
LC STN Files: CA, CAPLUS, USPATFULL



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


2 REFERENCES IN FILE CA (1957 TO DATE)  
2 REFERENCES IN FILE CAPLUS (1957 TO DATE)

L18 ANSWER 11 OF 14 REGISTRY COPYRIGHT 2003 ACS  
RN **216167-83-8** REGISTRY  
CN 2-Furancarboxylic acid, 5-nitro-, 4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-



hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenyl  
ester (9CI) (CA INDEX NAME)

FS 3D CONCORD  
MF C36 H49 N O6 S2  
SR CA  
LC STN Files: CA, CAPLUS, USPATFULL



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1957 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1957 TO DATE)


L18 ANSWER 12 OF 14 REGISTRY COPYRIGHT 2003 ACS

RN 216167-82-7 REGISTRY

CN Butanedioic acid, mono[4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenyl] ester (9CI) (CA INDEX NAME)

OTHER NAMES:

CN AGI 1067  
FS 3D CONCORD  
MF C35 H52 O5 S2  
SR CA  
LC STN Files: BIOSIS, CA, CAPLUS, CASREACT, DRUGNL, DRUGUPDATES, SYNTHLINE, TOXCENTER, USPATFULL



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

9 REFERENCES IN FILE CA (1957 TO DATE)  
9 REFERENCES IN FILE CAPLUS (1957 TO DATE)


L18 ANSWER 13 OF 14 REGISTRY COPYRIGHT 2003 ACS

RN 216167-81-6 REGISTRY

CN Phenol, 4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-[(4-nitrophenyl)methoxy]phenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)

FS 3D CONCORD


MF C38 H53 N O4 S2  
 SR CA  
 LC STN Files: CA, CAPLUS, USPATFULL



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1957 TO DATE)  
 1 REFERENCES IN FILE CAPLUS (1957 TO DATE)

L18 ANSWER 14 OF 14 REGISTRY COPYRIGHT 2003 ACS  
 RN **216167-80-5** REGISTRY  
 CN Pentanedioic acid, 4-[[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenyl methyl ester (9CI) (CA INDEX NAME)  
 FS 3D CONCORD  
 MF C37 H56 O5 S2  
 SR CA  
 LC STN Files: CA, CAPLUS, USPATFULL



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

2 REFERENCES IN FILE CA (1957 TO DATE)  
 2 REFERENCES IN FILE CAPLUS (1957 TO DATE)

=> s 216167-82-7 or 216167-80-5 or 216167-84-9  
 1 216167-82-7  
 (216167-82-7/RN)  
 1 216167-80-5  
 (216167-80-5/RN)  
 1 216167-84-9  
 (216167-84-9/RN)

L19 3 216167-82-7 OR 216167-80-5 OR 216167-84-9

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

FULL ESTIMATED COST	ENTRY 26.32	SESSION 302.36
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-7.16

FILE 'CAPLUS' ENTERED AT 11:32:42 ON 25 MAY 2003  
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
 COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 25 May 2003 VOL 138 ISS 22  
 FILE LAST UPDATED: 23 May 2003 (20030523/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s 119

L20 9 L19

=> d ibib abs hitstr 1-9

L20 ANSWER 1 OF 9 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2002:849415 CAPLUS

DOCUMENT NUMBER: 137:333157

TITLE: Probucol monoesters for increasing levels and improving functionality of plasma HDL cholesterol

INVENTOR(S): Luchoomun, Jayraz; Saxena, Uday; Sundell, Cynthia L.; Sikorski, James A.

PATENT ASSIGNEE(S): Atherogenics, Inc., USA

SOURCE: PCT Int. Appl., 161 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002087556	A2	20021107	WO 2002-US12678	20020411
WO 2002087556	A3	20030206		
WO 2002087556	C2	20030320		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,  
CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,  
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2003064967 A1 20030403 US 2002-122516 20020411

PRIORITY APPLN. INFO.:

US 2001-283376P P 20010411

US 2001-345025P P 20011109

OTHER SOURCE(S): MARPAT 137:333157

AB It has been discovered that certain selected probucol monoesters, and their pharmaceutically acceptable salts or prodrugs, are useful for increasing circulating HDL cholesterol. These compds. may also improve HDL functionality by (a) increasing clearance of cholesteryl esters, (b) increasing HDL-particle affinity for hepatic cell surface receptors, or (c) increasing the half-life of apoAI-HDL. The pharmaceutical compns. comprise probucol monoesters alone or in combination with other agents, e.g, statins, IBAT inhibitors, MTP inhibitors, cholesterol absorption inhibitors, phytosterols, CETP inhibitors, fibric acid derivs., and antihypertensive agents. For example, mono[4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenyl]ester of pentanedioic acid, prepd. from probucol and glutaric anhydride, elevated HDLc in hyperlipidemic hamster by 22% (av. of 3 expts., range 5-44%), compared to untreated controls after 2 wk treatment at a dose of 150 mg/kg/day. LDLc was reduced by 29% on av., VLDL cholesterol by 42%, and triglycerides by 24%, compared to controls. The compd. was well tolerated and all animals gained wt.


IT 216167-80-5P 216167-82-7P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of probucol monoesters for increasing levels and improving functionality of plasma HDL cholesterol)


RN 216167-80-5 CAPLUS

CN Pentanedioic acid, 4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenyl methyl ester (9CI) (CA INDEX NAME)



RN 216167-82-7 CAPLUS

CN Butanedioic acid, mono[4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenyl] ester (9CI) (CA INDEX NAME)



L20 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2002:814837 CAPLUS

DOCUMENT NUMBER: 137:320305

TITLE: Probucol derivatives and methods for treating transplant rejection

INVENTOR(S): Edwards, David B.; Somers, Patricia K.; Glass, Mitchell

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 22 pp., Cont.-in-part of U.S. Ser. No. 815,262.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 4

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002156022	A1	20021024	US 2001-36307	20011025
US 6147250	A	20001114	US 1998-79213	19980514
US 6548699	B1	20030415	US 1999-370046	19990806
US 2002016300	A1	20020207	US 2001-815262	20010321
US 2002177717	A1	20021128	US 2002-60734	20020130
US 2002169215	A1	20021114	US 2002-114346	20020402
US 2002188118	A1	20021212	US 2002-115206	20020402
US 2002193446	A1	20021219	US 2002-114351	20020402

PRIORITY APPLN. INFO.:

US 1997-47020P	P	19970514
US 1998-79213	A1	19980514
US 1999-370046	A2	19990806
US 2000-191046P	P	20000321
US 2001-815262	A2	20010321

OTHER SOURCE(S): MARPAT 137:320305

GI




AB The invention discloses the use of I [R1-R4 = H, OH, C1-10 alkyl, aryl, heteroaryl, etc.; Y = bond, C(O); Z = C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, etc.], and pharmaceutically acceptable salts thereof, alone or in combination, for the treatment of transplant rejection. Prepn. of I [R1-R4 = tert-butyl; YZ = (CH2)3COOH] from probucol which was evaluated in a graft arteriopathy model and Me 4-chlorobutyrate is described.

IT 216167-82-7

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(probucol derivs. for treatment of transplant rejection)

RN 216167-82-7 CAPLUS

CN Butanedioic acid, mono[4-[[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenyl] ester (9CI) (CA INDEX NAME)



L20 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2002:641096 CAPLUS

DOCUMENT NUMBER: 138:313884

TITLE: Novel phenolic antioxidants as multifunctional inhibitors of inducible VCAM-1 expression for use in atherosclerosis

AUTHOR(S): Meng, Charles Q.; Somers, Patricia K.; Rachita, Carolyn L.; Holt, Lisa A.; Hoong, Lee K.; Zheng, X. Sharon; Simpson, Jacob E.; Hill, Russell R.; Olliff, Lynda K.; Kunsch, Charles; Sundell, Cynthia L.; Parthasarathy, Sampath; Saxena, Uday; Sikorski, James A.; Wasserman, Martin A.

CORPORATE SOURCE: AtheroGenics, Inc., Alpharetta, GA, 30004, USA

SOURCE: Bioorganic & Medicinal Chemistry Letters (2002), 12(18), 2545-2548

CODEN: BMCLE8; ISSN: 0960-894X

PUBLISHER: Elsevier Science Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB A series of novel phenolic compds. has been discovered as potent inhibitors of TNF- $\alpha$ -inducible expression of vascular cell adhesion mol.-1 (VCAM-1) with concurrent antioxidant and lipid-modulating properties. Optimization of these multifunctional agents led to the identification of AGI-1067 as a clin. candidate with demonstrated efficacies in animal models of atherosclerosis and hyperlipidemia.


IT 216167-82-7, AGI-1067

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(phenolic antioxidants as inhibitors of inducible VCAM-1 expression for use in atherosclerosis)

RN 216167-82-7 CAPLUS

CN Butanedioic acid, mono[4-[[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenyl] ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2002:580040 CAPLUS

DOCUMENT NUMBER: 138:130391  
 TITLE: AGI-1067 AtheroGenics  
 AUTHOR(S): Hatch, Grant M.  
 CORPORATE SOURCE: Department of Pharmacology and Therapeutics Faculty of  
 Medicine, University of Manitoba, Winnipeg, MB, R3E  
 0T6, Can.  
 SOURCE: Current Opinion in Investigational Drugs (PharmaPress  
 Ltd.) (2002), 3(3), 433-436  
 CODEN: COIDAZ; ISSN: 1472-4472  
 PUBLISHER: PharmaPress Ltd.  
 DOCUMENT TYPE: Journal; General Review  
 LANGUAGE: English


AB A review. AGI-1067 is an oral VCAM-1 (vascular cell adhesion mol.-1) gene  
 expression inhibitor under development by AtheroGenics for the potential  
 prevention of atherosclerosis (hypercholesterolemia) and restenosis.  
 AGI-1067 was also being developed in collaboration with Schering-Plough;  
 however, in Oct. 2001, all rights to the drug were returned to  
 AtheroGenics. In Feb. 2001, dosing was completed in phase II trials for  
 the potential treatment and prevention of restenosis and atherosclerosis  
 following angioplasty. In Dec. 2001, further phase II trials (CART-2)  
 were initiated for the treatment of restenosis and atherosclerosis.  
 Early-phase clin. trials are ongoing for the prevention of  
 atherosclerosis. In Jan. 2002, analysts at Adams, Harkness & Hill  
 predicted that AGI-1067 would be launched in the second half of 2005, with  
 sales of US \$100 m in that year and US \$540 m in 2006. It was also  
 believed that AtheroGenics would look to sign a marketing partnership  
 following the expected completion of the CART-2 trial in 2002.

IT 216167-82-7, AGI 1067

RL: ADV (Adverse effect, including toxicity); DMA (Drug mechanism of  
 action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
 (Biological study); USES (Uses)  
 (AGI-1067 pharmacol. and clin. development)

RN 216167-82-7 CAPLUS

CN Butanedioic acid, mono[4-[[[1-[[3,5-bis(1,1-dimethylethyl)-4-  
 hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenyl]  
 ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS  
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2001:863541 CAPLUS

DOCUMENT NUMBER: 135:371524

TITLE: Process for preparing water-soluble probucol acyl  
 esters for use as food antioxidants

INVENTOR(S): Jass, Paul Alan

PATENT ASSIGNEE(S): Salsbury Chemicals, Inc., USA

SOURCE: U.S., 5 pp.  
 CODEN: USXXAM



DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6323359	B1	20011127	US 2000-562657	20000502
PRIORITY APPLN. INFO.:			US 2000-562657	20000502
OTHER SOURCE(S):			CASREACT 135:371524; MARPAT 135:371524	
GI				



AB Water-sol. derivs. of probucol compds. [I; R1, R2 = alkyl, alkenyl, aryl; R3-R6 = C1-4 alkyl; X, Y = H, (un)satd. (un)substituted C1-8 acyl] (e.g., probucol mono- and disuccinate), useful as food antioxidants, are prepd. by the reaction of a soln. of a probucol compd. (II) with an alkali metal hydroxide, alkali metal alkoxide (e.g., potassium tert-butoxide), alkylammonium alkoxide, alkylammonium hydroxide and mixts. forming an ammonium or an alkali metal salt of the probucol compd. and reacting the salt with a carboxylic acid anhydride selected from succinic anhydride, glutaric anhydride, adipic anhydride, suberic anhydride, sebacic anhydride, azelaic anhydride, phthalic anhydride, and maleic anhydride.

IT **216167-82-7P**


RL: FFD (Food or feed use); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)

(process for prepg. water-sol. probucol acyl esters for use as food antioxidants)

RN 216167-82-7 CAPLUS

CN Butanedioic acid, mono[4-[[[1-[[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenyl] ester (9CI) (CA INDEX NAME)





REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2000:335659 CAPLUS

DOCUMENT NUMBER: 132:343330

TITLE: Methods and compositions to lower plasma cholesterol levels

INVENTOR(S): Medford, Russell M.; Saxena, Uday

PATENT ASSIGNEE(S): Atherogenics, Inc., USA

SOURCE: PCT Int. Appl., 50 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000028332	A1	20000518	WO 1999-US26519	19991109
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1137948	A1	20011004	EP 1999-962732	19991109
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002529740	T2	20020910	JP 2000-581459	19991109
PRIORITY APPLN. INFO.: US 1998-107644P P 19981109				
WO 1999-US26519 W 19991109				


AB A method for detg. whether a compd. binds to a lipoprotein, e.g. LDL or VLDL, in a manner which will lower plasma cholesterol is provided that includes assessing the ability of the compd. to form a complex with the lipoprotein, e.g., LDL or VLDL, and then detg. whether the newly formed complex causes a change in the structure of apoB-100 that results in increased binding affinity to the LDL receptor. Also disclosed is a method for lowering cholesterol in a host in need thereof, including a human, that includes the administration of an effective amt. of a compd. which binds to cholesterol-carrying lipoprotein (e.g. LDL or VLDL) in a manner that alters the three dimensional configuration of the lipoprotein and increases the binding affinity of the apoB-100 protein to the LDL receptor, including those on the surface of a hepatic cell.

IT 216167-82-7 216167-84-9


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(methods and compns. to lower plasma cholesterol levels)

RN 216167-82-7 CAPLUS  
 CN Butanedioic acid, mono[4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenyl] ester (9CI) (CA INDEX NAME)



RN 216167-84-9 CAPLUS  
 CN Butanoic acid, 4-[4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-dimethylphenoxy]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 7 OF 9 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1999:48609 CAPLUS

DOCUMENT NUMBER: 130:119591

TITLE: Antioxidant enhancement of therapy for hyperproliferative conditions

INVENTOR(S): Chinery, Rebecca; Beauchamp, R. Daniel; Coffey, Robert J.; Medford, Russell M.; Wadsinski, Brian

PATENT ASSIGNEE(S): Atherogenics, Inc., USA

SOURCE: PCT Int. Appl., 112 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9901118	A2	19990114	WO 1998-US13750	19980701
WO 9901118	A3	19990422		
W: AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GE, HU, ID, IL, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9882827	A1	19990125	AU 1998-82827	19980701
EP 1019034	A2	20000719	EP 1998-933078	19980701

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
IE, SI, LT, LV, FI, RO

JP 2002511878 T2 20020416  
US 2001049349 A1 20011206

JP 1999-507360 19980701  
US 2001-779086 20010207

PRIORITY APPLN. INFO.:

US 1997-886653 A 19970701  
US 1997-967492 A 19971111  
US 1998-108609 B1 19980701  
WO 1998-US13750 W 19980701

OTHER SOURCE(S): MARPAT 130:119591

AB A method to enhance the cytotoxic activity of an antineoplastic drug comprises administering an effective amt. of the antineoplastic drug to a host exhibiting abnormal cell proliferation in combination with an effective cytotoxicity-increasing amt. of an antioxidant. The invention also includes a method to decrease the toxicity to an antineoplastic agent or increase the therapeutic index of an antineoplastic agent administered for the treatment of a solid growth of abnormally proliferating cells, comprising administering an antioxidant prior to, with, or following the antineoplastic treatment.


IT 216167-82-7

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(antioxidant enhancement of therapy for hyperproliferative conditions)

RN 216167-82-7 CAPLUS

CN Butanedioic acid, mono[4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenyl] ester (9CI) (CA INDEX NAME)



L20 ANSWER 8 OF 9 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1998:761875 CAPLUS

DOCUMENT NUMBER: 130:13646

TITLE: Preparation of phenolic compounds for the inhibition of the expression of VCAM-1

INVENTOR(S): Medford, Russell M.; Somers, Patricia K.; Hoong, Lee K.; Meng, Charles Q.

PATENT ASSIGNEE(S): Atherogenics, Inc., USA

SOURCE: PCT Int. Appl., 109 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 4

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9851662	A2	19981119	WO 1998-US9781	19980514
WO 9851662	A3	20000302		

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX,

NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT,  
 UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM  
 RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,  
 PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG

AU 9874851 A1 19981208 AU 1998-74851 19980514

AU 750041 B2 20020711

EP 994853 A2 20000426 EP 1998-922264 19980514

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
 IE, SI, LT, LV, FI, RO

US 6121319 A 20000919 US 1998-78935 19980514

BR 9809819 A 20010918 BR 1998-9819 19980514

JP 2002503227 T2 20020129 JP 1998-549502 19980514

NO 9905544 A 20000110 NO 1999-5544 19991112


MX 9910402 A 20000630 MX 1999-10402 19991112

PRIORITY APPLN. INFO.: US 1997-47020P P 19970514

WO 1998-US9781 W 19980514

OTHER SOURCE(S): MARPAT 130:13646

GI




AB Title compds. [e.g., I; R = Z1Z2R5; R1,R2 = (un)substituted (cyclo)alkyl, -(hetero)aryl, etc.; R3,R4 = any group that does not otherwise adversely affect (sic) the desired properties of the mol. including H, halogen, or R1 (sic); R5 = (di)(alkyl)amino, alkyl, alkoxy(carbonyl), (hetero)aryl, etc.; Z1 = O SOO-2, NH, CH2; Z2 = bond, alkylene(oxy) aryleneoxy, etc.] were prepd. Thus, 4-(BrCH2)C6H4CH2CO2H was thioetherified by 4-mercapto-2,6-di-tert-butylphenol to give I [R = SCH2C6H4(CH2CO2H)-4, R1 = R2 = CMe3, R3 = R4 = H]. Data for biol. activity of I were given.

IT **216167-80-5P 216167-82-7P 216167-84-9P**


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (prepn. of phenolic compds. for the inhibition of the expression of VCAM-1)

RN 216167-80-5 CAPLUS


CN Pentanedioic acid, 4-[[[1-[[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenyl methyl ester (9CI) (CA INDEX NAME)



RN 216167-82-7 CAPLUS  
 CN Butanedioic acid, mono[4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenyl] ester (9CI) (CA INDEX NAME)



RN 216167-84-9 CAPLUS  
 CN Butanoic acid, 4-[4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-dimethylphenoxy]- (9CI) (CA INDEX NAME)



L20 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1998:761806 CAPLUS

DOCUMENT NUMBER: 130:20572

TITLE: Monoesters of probucol for the treatment of cardiovascular and inflammatory disease

INVENTOR(S): Medford, Russell M.; Somers, Patricia K.

PATENT ASSIGNEE(S): Atherogenics, Inc., USA

SOURCE: PCT Int. Appl., 36 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 4

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9851289	A2	19981119	WO 1998-US9773	19980514
WO 9851289	A3	19990514		
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9875711	A1	19981208	AU 1998-75711	19980514
AU 747801	B2	20020523		
EP 981343	A2	20000301	EP 1998-923411	19980514
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				

IE, SI, LT, LV, FI, RO			
BR 9809793	A	20000627	BR 1998-9793 19980514
NZ 501069	A	20000728	NZ 1997-501069 19980514
US 6121319	A	20000919	US 1998-78935 19980514
JP 2001524986	T2	20011204	JP 1998-549498 19980514
NO 9905543	A	20000110	NO 1999-5543 19991112
MX 9910404	A	20000630	MX 1999-10404 19991112
PRIORITY APPLN. INFO.:			US 1997-47020P P 19970514
			WO 1998-US9773 W 19980514


AB This invention is a method and compn. for the inhibition of VCAM-1, and in particular for the treatment of cardiovascular or inflammatory disease, including atherosclerosis, that includes the administration of an effective amt. of an ester of probucol. Rabbits were fed high fat chow (0.5% cholesterol and 3% coconut oil) contg. 0.5% probucol monosuccinate (I) for 3wk. I caused a significant redn. in all lipoprotein fractions.

IT **216167-82-7**

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(monoesters of probucol for treatment of cardiovascular and inflammatory disease)

RN 216167-82-7 CAPLUS

CN Butanedioic acid, mono[4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenyl] ester (9CI) (CA INDEX NAME)



=> file reg

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
41.24	343.60

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
-5.86	-13.02

CA SUBSCRIBER PRICE

FILE 'REGISTRY' ENTERED AT 11:33:34 ON 25 MAY 2003

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 23 MAY 2003 HIGHEST RN 519387-75-8

DICTIONARY FILE UPDATES: 23 MAY 2003 HIGHEST RN 519387-75-8

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2003

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details:  
<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=> s 216167-93-0 or 216167-94-1 or 216167-95-2 or 216167-96-3 or 216167-97-4 or 216167-98-5 or 216167-99-6 or 216168-00-2 or 216168-01-3 or 216168-02-4 or 216168-03-5 or 216168-5-7

1 216167-93-0  
(216167-93-0/RN)

1 216167-94-1  
(216167-94-1/RN)

1 216167-95-2  
(216167-95-2/RN)

1 216167-96-3  
(216167-96-3/RN)

1 216167-97-4  
(216167-97-4/RN)

1 216167-98-5  
(216167-98-5/RN)

1 216167-99-6  
(216167-99-6/RN)

1 216168-00-2  
(216168-00-2/RN)

1 216168-01-3  
(216168-01-3/RN)

1 216168-02-4  
(216168-02-4/RN)

1 216168-03-5  
(216168-03-5/RN)

1 216168

8160324 5

3042708 7

0 216168-5-7  
(216168(W)5(W)7)

L21 11 216167-93-0 OR 216167-94-1 OR 216167-95-2 OR 216167-96-3 OR 216167-97-4 OR 216167-98-5 OR 216167-99-6 OR 216168-00-2 OR 216168-01-3 OR 216168-02-4 OR 216168-03-5 OR 216168-5-7

=> d 1-11

L21 ANSWER 1 OF 11 REGISTRY COPYRIGHT 2003 ACS

RN **216168-03-5** REGISTRY


CN 1,2-Propanediol, 3-[4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenoxy]-(9CI) (CA INDEX NAME)

FS 3D CONCORD

MF C34 H54 O4 S2

SR CA


LC STN Files: CA, CAPLUS, USPATFULL



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1957 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1957 TO DATE)


L21 ANSWER 2 OF 11 REGISTRY COPYRIGHT 2003 ACS  
RN **216168-02-4** REGISTRY  
CN Phenol, 4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-(3-ethoxy-2-hydroxypropoxy)phenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)-(9CI) (CA INDEX NAME)  
FS 3D CONCORD  
MF C36 H58 O4 S2  
SR CA  
LC STN Files: CA, CAPLUS, USPATFULL



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1957 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1957 TO DATE)

L21 ANSWER 3 OF 11 REGISTRY COPYRIGHT 2003 ACS  
RN **216168-01-3** REGISTRY  
CN 1,2,3-Butanetriol, 4-[4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenoxy]-(9CI) (CA INDEX NAME)  
FS 3D CONCORD  
MF C35 H56 O5 S2  
SR CA  
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

2 REFERENCES IN FILE CA (1957 TO DATE)  
2 REFERENCES IN FILE CAPLUS (1957 TO DATE)

L21 ANSWER 4 OF 11 REGISTRY COPYRIGHT 2003 ACS




RN 216168-00-2 REGISTRY  
 CN Glycine, N-[3-[4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenoxy]-2-hydroxypropyl]-  
 (9CI) (CA INDEX NAME)  
 FS 3D CONCORD  
 MF C36 H57 N O5 S2  
 SR CA  
 LC STN Files: CA, CAPLUS, USPATFULL



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

2 REFERENCES IN FILE CA (1957 TO DATE)  
 2 REFERENCES IN FILE CAPLUS (1957 TO DATE)

L21 ANSWER 5 OF 11 REGISTRY COPYRIGHT 2003 ACS  
 RN 216167-99-6 REGISTRY  
 CN Phenol, 4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-(oxiranylmethoxy)phenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)  
 FS 3D CONCORD  
 MF C34 H52 O3 S2  
 SR CA  
 LC STN Files: CA, CAPLUS, USPATFULL




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1957 TO DATE)  
 1 REFERENCES IN FILE CAPLUS (1957 TO DATE)

L21 ANSWER 6 OF 11 REGISTRY COPYRIGHT 2003 ACS  
 RN 216167-98-5 REGISTRY  
 CN Oxiranemethanol, .alpha.-[[[3-[[4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenoxy]methyl]oxiranyl]methoxy]methyl]- (9CI) (CA INDEX NAME)  
 FS 3D CONCORD  
 MF C39 H60 O6 S2


SR CA  
LC STN Files: CA, CAPLUS, USPATFULL



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1957 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1957 TO DATE)


L21 ANSWER 7 OF 11 REGISTRY COPYRIGHT 2003 ACS  
RN **216167-97-4** REGISTRY  
CN Oxiranemethanol, 3-[[4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenoxy]methyl]- (9CI) (CA INDEX NAME)  
FS 3D CONCORD  
MF C35 H54 O4 S2  
SR CA  
LC STN Files: CA, CAPLUS, USPATFULL



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1957 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1957 TO DATE)


L21 ANSWER 8 OF 11 REGISTRY COPYRIGHT 2003 ACS  
RN **216167-96-3** REGISTRY  
CN Oxiranemethanol, .alpha.-[[4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenoxy]methyl]- (9CI) (CA INDEX NAME)  
FS 3D CONCORD  
MF C35 H54 O4 S2  
SR CA  
LC STN Files: CA, CAPLUS, USPATFULL



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1957 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1957 TO DATE)


L21 ANSWER 9 OF 11 REGISTRY COPYRIGHT 2003 ACS  
RN **216167-95-2** REGISTRY  
CN Butanoic acid, 4-[[4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenoxy]- (9CI) (CA INDEX NAME)  
FS 3D CONCORD  
MF C35 H54 O4 S2  
SR CA  
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

3 REFERENCES IN FILE CA (1957 TO DATE)  
3 REFERENCES IN FILE CAPLUS (1957 TO DATE)


L21 ANSWER 10 OF 11 REGISTRY COPYRIGHT 2003 ACS  
RN **216167-94-1** REGISTRY  
CN Pentanedioic acid, mono[4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenyl] ester (9CI) (CA INDEX NAME)  
FS 3D CONCORD  
MF C36 H54 O5 S2  
SR CA  
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

6 REFERENCES IN FILE CA (1957 TO DATE)  
6 REFERENCES IN FILE CAPLUS (1957 TO DATE)

L21 ANSWER 11 OF 11 REGISTRY COPYRIGHT 2003 ACS  
RN **216167-93-0** REGISTRY  
CN Glycine, 4-[[[1-[[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenyl ester (9CI) (CA INDEX NAME)  
FS 3D CONCORD  
MF C33 H51 N O3 S2  
SR CA  
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

3 REFERENCES IN FILE CA (1957 TO DATE)  
3 REFERENCES IN FILE CAPLUS (1957 TO DATE)

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	33.94	377.54
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-13.02

FILE 'CAPLUS' ENTERED AT 11:37:46 ON 25 MAY 2003  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December

26, 1996), unless otherwise indicated in the original publications.  
 The CA Lexicon is the copyrighted intellectual property of the  
 American Chemical Society and is provided to assist you in searching  
 databases on STN. Any dissemination, distribution, copying, or storing  
 of this information, without the prior written consent of CAS, is  
 strictly prohibited.

FILE COVERS 1907 - 25 May 2003 VOL 138 ISS 22  
 FILE LAST UPDATED: 23 May 2003 (20030523/ED)

This file contains CAS Registry Numbers for easy and accurate  
 substance identification.

=> s 216167-93-0

**REGISTRY INITIATED**

Substance data SEARCH and crossover from CAS REGISTRY in progress...  
 Use DISPLAY HITSTR (or FHITSTR) to directly view retrieved structures.

L23 3 L22


=> d ibib abs 3

L23 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1998:761875 CAPLUS  
 DOCUMENT NUMBER: 130:13646  
 TITLE: Preparation of phenolic compounds for the inhibition  
 of the expression of VCAM-1  
 INVENTOR(S): Medford, Russell M.; Somers, Patricia K.; Hoong, Lee  
 K.; Meng, Charles Q.  
 PATENT ASSIGNEE(S): Atherogenics, Inc., USA  
 SOURCE: PCT Int. Appl., 109 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 4  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9851662	A2	19981119	WO 1998-US9781	19980514
WO 9851662	A3	20000302		
W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
AU 9874851	A1	19981208	AU 1998-74851	19980514
AU 750041	B2	20020711		
EP 994853	A2	20000426	EP 1998-922264	19980514
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
US 6121319	A	20000919	US 1998-78935	19980514
BR 9809819	A	20010918	BR 1998-9819	19980514

JP 2002503227 T2 20020129 JP 1998-549502 19980514  
 NO 9905544 A 20000110 NO 1999-5544 19991112  
 MX 9910402 A 20000630 MX 1999-10402 19991112  
 PRIORITY APPLN. INFO.: US 1997-47020P P 19970514  
 WO 1998-US9781 W 19980514  
 OTHER SOURCE(S): MARPAT 130:13646  
 GI



AB Title compds. [e.g., I; R = Z1Z2R5; R1,R2 = (un)substituted (cyclo)alkyl, -(hetero)aryl, etc.; R3,R4 = any group that does not otherwise adversely affect (sic) the desired properties of the mol. including H, halogen, or R1 (sic); R5 = (di)(alkyl)amino, alkyl, alkoxy(carbonyl), (hetero)aryl, etc.; Z1 = O SOO-2, NH, CH2; Z2 = bond, alkylene(oxy) aryleneoxy, etc.] were prepd. Thus, 4-(BrCH2)C6H4CH2CO2H was thioetherified by 4-mercapto-2,6-di-tert-butylphenol to give I [R = SCH2C6H4(CH2CO2H)-4, R1 = R2 = CMe3, R3 = R4 = H]. Data for biol. activity of I were given.

=> d hitstr


L23 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2003 ACS

IT **216167-93-0**

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (probucol derivs. for treatment of transplant rejection)

RN 216167-93-0 CAPLUS

CN Glycine, 4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenyl ester (9CI) (CA INDEX NAME)




=> s 13

L24 14 L3

=> d ibib abs hitstr 14

L24 ANSWER 14 OF 14 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1986:28675 CAPLUS  
 DOCUMENT NUMBER: 104:28675  
 TITLE: New derivatives of clofibrate and probucol.  
 Preliminary studies on hypolipemic activity  
 AUTHOR(S): De Meglio, P.; Ravenna, F.; Manzardo, S.; Gentili, P.;  
 Riva, M.  
 CORPORATE SOURCE: Lab. Ric., Maggioni Farmaceutici S.p.A., Milan, Italy  
 SOURCE: Farmaco, Edizione Scientifica (1985), 40(11), 833-44  
 CODEN: FRPSAX; ISSN: 0430-0920  
 DOCUMENT TYPE: Journal  
 LANGUAGE: Italian  
 GI




AB Two types of compds. were prepd: (a) clofibrate analogs without the Cl atom and contg. a cyclohexyl or phenylcyclohexyl group in place of the Ph group, or contg. the hydroxybutyrate group of clofibrate attached to the 4- and 4'-positions of a biphenyl moiety; (b) probucol analogs in which the hydroxybutyrate group of clofibrate was attached to one or both of the arom. rings of probucol. Some compds. of both classes had hypolipemic activity in mice and rats; one of these, I [99661-82-2], a probucol analog, also did not produce the hepatomegaly assocd. as a side effect with the other compds. and is suitable for further testing.

IT 99661-86-6P 99661-87-7P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)  
 (prepn. and hypolipemic activity of)


RN 99661-86-6 CAPLUS

CN Propanoic acid, 2-[4-[[1-[(4-hydroxyphenyl)thio]-1-methylethyl]thio]phenoxy]-2-methyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 99661-87-7 CAPLUS

CN Propanoic acid, 2-[4-[[1-[(4-hydroxyphenyl)thio]-1-methylethyl]thio]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



=> d ibib abs hitstr 13

L24 ANSWER 13 OF 14 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1991:558965 CAPLUS

DOCUMENT NUMBER: 115:158965

TITLE: Preparation of 6-aryloxymethyl-4-hydroxytetrahydropyran-2-ones and the corresponding dihydroxycarboxylic acids and salts as HMG-CoA reductase inhibitors and biological antioxidants

INVENTOR(S): Jendralla, Heiner; Wess, Guenther; Kessler, Kurt; Beck, Gerhard

PATENT ASSIGNEE(S): Hoechst A.-G., Germany

SOURCE: Eur. Pat. Appl., 59 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 418648	A1	19910327	EP 1990-117043	19900905
EP 418648	B1	19950111		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
DE 3929913	A1	19910404	DE 1989-3929913	19890908
ES 2067609	T3	19950401	ES 1990-117043	19900905
US 5294724	A	19940315	US 1990-578240	19900906
CA 2024849	AA	19910309	CA 1990-2024849	19900907
CA 2024849	C	20020101		
NO 9003911	A	19910311	NO 1990-3911	19900907
NO 175002	B	19940509		
NO 175002	C	19940817		
AU 9062277	A1	19910314	AU 1990-62277	19900907
AU 629977	B2	19921015		
JP 03099075	A2	19910424	JP 1990-235998	19900907
JP 3053417	B2	20000619		
ZA 9007134	A	19910626	ZA 1990-7134	19900907
HU 56085	A2	19910729	HU 1990-5827	19900907
HU 212103	B	19960228		
IL 95599	A1	19990714	IL 1990-95599	19901006
FI 9603396	A	19960830	FI 1996-3396	19960830

PRIORITY APPLN. INFO.:


DE 1989-3929913 A 19890908

FI 1990-4395 A 19900906

OTHER SOURCE(S): MARPAT 115:158965

GI





AB Title compds. [I; X, Y = O, S; R1, R5 = Me2CH, cyclopropyl, (un)substituted Ph; R2, R4 = H, Me2CH, cyclopropyl, (un)substituted Ph; R3 = H, Me, Et, C3-8 alkyl optionally substituted by thiophenyl residue Q in which X, R1, R2, R4, R5 are as above, Z = H, pharmaceutically compatible cation, hydroxypyranyl residue Q1, dihydroxyhexanoic acid residue Q2 (R6 = OH, R7 = H), C3-8 cycloalkyl, (un)substituted Ph, acetyl (when Y = O)], open chain carboxylic acid forms (II; R1-R5, X, Y as defined) and their pharmaceutically compatible esters or salts with bases, useful as antihypercholesteremics and for the prophylaxis and treatment of arteriosclerosis, were prepd. Reaction of 2-(p-fluorophenyl)-4-isothiocyanato-6-isopropylphenol (prepn. given) with 4-FC6H4MgBr gave 100% phenylthiophenol deriv. which underwent a substitution reaction (74.0%) with 6-mesyloxydihydroxyhexanoate tert-Bu ester acetone Q2OSO2Me (R6 = CMe3, R7R7 = CMe2). The product was deprotected (80.8%) and saponified to give 93% the title compd. 3(R),5(S)-dihydroxy-6-[2-p-fluorophenyl-4-p-fluorophenylthio-6-isopropyl]phenoxyhexanoate Na salt (III). The latter in vitro inhibited rat liver microsomal HMG CoA reductase with IC50 of 6 .times. 10-9 M, vs. 8 .times. 10-9 M for mevinolin Na salt.


IT **136006-85-4P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(prepn. and deprotection of, in prepn. of drug)

RN 136006-85-4 CAPLUS

CN D-erythro-Hexonic acid, 2,4-dideoxy-6-O-[4'-fluoro-5-[[1-[[4'-fluoro-6-hydroxy-5-(1-methylethyl)[1,1'-biphenyl]-3-yl]thio]-1-methylethyl]thio]-3-(1-methylethyl)[1,1'-biphenyl]-2-yl]-3,5-O-(1-methylethylidene)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



—OBu-t

IT 136006-89-8P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. and sapon. of, in prepn. of drug)

RN 136006-89-8 CAPLUS

CN D-erythro-Hexonic acid, 2,4-dideoxy-6-O-[4'-fluoro-5-[[1-[[4'-fluoro-6-hydroxy-5-(1-methylethyl)[1,1'-biphenyl]-3-yl]thio]-1-methylethyl]thio]-3-(1-methylethyl)[1,1'-biphenyl]-2-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RL: SPN (Synthetic preparation); PREP (Preparation)  
(prepn. of, as HMG-CoA reductase inhibitor and biol. antioxidant)

CN D-erythro-Hexonic acid, 2,4-dideoxy-6-O-[4'-fluoro-5-[[1-[4'-fluoro-6-hydroxy-5-(1-methylethyl)[1,1'-biphenyl]-3-yl]thio]-1-methylethyl]thio]-3-(1-methylethyl)[1,1'-biphenyl]-2-yl]-, sodium salt (9CI) (CA INDEX NAME)

Chemical structure of compound 10: A bis-thioether derivative. It consists of two 3-(4-fluorophenyl)-5-hydroxy-2-isopropylphenyl groups connected by a 1,1-dimethyl-2,2'-disulfanyldimethane bridge. The right-hand phenyl ring is further substituted with a 2-hydroxy-3-((R)-2-hydroxy-3-oxopropyl)ethoxy chain.

 $\bullet_x \text{Na}$ 

L24 ANSWER 12 OF 14 CAPLUS COPYRIGHT 2003 ACS  
ACCESSION NUMBER: 1991:583017 CAPLUS  
DOCUMENT NUMBER: 115:183017  
TITLE: Synthesis and biological activity of new HMG-CoA  
reductase inhibitors. 3. Lactones of  
6-phenoxy-3,5-dihydroxyhexanoic acids  
AUTHOR(S): Jendralla, H.; Granzer, E.; Von Kerekjarto, B.;  
Krause, R.; Schacht, U.; Baader, E.; Bartmann, W.;  
Beck, G.; Bergmann, A.; et al.  
CORPORATE SOURCE: Hoechst A.-G., Frankfurt/Main, D-6230/80, Germany  
SOURCE: Journal of Medicinal Chemistry (1991), 34(10), 2962-83  
CODEN: JMCMAR; ISSN: 0022-2623  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
GI



AB Forty three optically active sodium dihydroxyphenoxylexanoates, e.g., I [R = Cl, Me, cyclopentyl, CHMe<sub>2</sub>; R<sub>1</sub> = H, R<sub>2</sub> = Cl, Me, CHMe<sub>2</sub>, CMe<sub>3</sub>, 4-C<sub>6</sub>H<sub>4</sub>F; R<sub>3</sub> = H, OCH<sub>2</sub>C<sub>6</sub>H<sub>4</sub>F-4; R<sub>4</sub> = CH(C<sub>6</sub>H<sub>4</sub>F-4)<sub>2</sub>, CHMe(C<sub>6</sub>H<sub>4</sub>F-4), (CH<sub>2</sub>)<sub>2</sub>OC<sub>6</sub>H<sub>4</sub>F-4] and the corresponding lactones II were prepd. from the resp. phenols III. A no. of the HMG-CoA reductase inhibitors I exceeded the activity of mevinolin in vitro. Selected lactones II effectively inhibited hepatic de novo cholesterol synthesis in rats in vivo. After administration to rabbits, I (R = CHMe<sub>2</sub>, R<sub>1</sub> = R<sub>3</sub> = H, R<sub>2</sub> = SC<sub>6</sub>H<sub>4</sub>F-4, R<sub>4</sub> = C<sub>6</sub>H<sub>4</sub>F-4) notably reduced plasma cholesterol levels more potently than mevinolin. Each of these compds. had only moderate activity after administration to dogs. One compd., a hybrid of the structural elements of probucol and HMG-CoA reductase inhibitors, after administration to rats decreased serum lipoproteins and increased HDL/LDL ratio better than probucol. HMG-CoA reductase inhibitor I (R = R<sub>1</sub> = R<sub>3</sub> = CHMe<sub>2</sub>, R<sub>2</sub> = OAc, R<sub>4</sub> = C<sub>6</sub>H<sub>4</sub>F-4), and 2 phenolic building blocks inhibited LDL oxidn. in vitro. Chem. structure-activity relationships and the pharmacol. profile of phenoxy-type inhibitors I diverged from those of known HMG-CoA reductase inhibitors.


IT **136034-02-1P**

RL: SPN (Synthetic preparation); PREP (Preparation)  
(prepn. and HMG-CoA reductase inhibition by)

RN 136034-02-1 CAPLUS

CN D-erythro-Hexonic acid, 2,4-dideoxy-6-O-[4'-fluoro-5-[[1-[[4'-fluoro-6-hydroxy-5-(1-methylethyl)[1,1'-biphenyl]-3-yl]thio]-1-methylethyl]thio]-3-(1-methylethyl)[1,1'-biphenyl]-2-yl]-, disodium salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 136006-85-4P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)  
(prepn. and deprotection of)

RN 136006-85-4 CAPLUS

CN D-erythro-Hexonic acid, 2,4-dideoxy-6-O-[4'-fluoro-5-[[1-[[4'-fluoro-6-  
hydroxy-5-(1-methylethyl)[1,1'-biphenyl]-3-yl]thio]-1-methylethyl]thio]-3-  
(1-methylethyl)[1,1'-biphenyl]-2-yl]-3,5-O-(1-methylethylidene)-,  
1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

—OBu-t


IT 136006-89-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)  
(prepn. and sapon. of)

RN 136006-89-8 CAPLUS

CN D-erythro-Hexonic acid, 2,4-dideoxy-6-O-[4'-fluoro-5-[[1-[[4'-fluoro-6-  
hydroxy-5-(1-methylethyl)[1,1'-biphenyl]-3-yl]thio]-1-methylethyl]thio]-3-  
(1-methylethyl)[1,1'-biphenyl]-2-yl]-, 1,1-dimethylethyl ester (9CI) (CA  
INDEX NAME)

Absolute stereochemistry.



— OBU-t

=> d ibib abs hitstr 11

L24 ANSWER 11 OF 14 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1998:761806 CAPLUS

DOCUMENT NUMBER: 130:20572

TITLE: Monoesters of probucol for the treatment of cardiovascular and inflammatory disease

INVENTOR(S): Medford, Russell M.; Somers, Patricia K.

PATENT ASSIGNEE(S): Atherogenics, Inc., USA

SOURCE: PCT Int. Appl., 36 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 4

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9851289	A2	19981119	WO 1998-US9773	19980514
WO 9851289	A3	19990514		
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9875711	A1	19981208	AU 1998-75711	19980514
AU 747801	B2	20020523		
EP 981343	A2	20000301	EP 1998-923411	19980514
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
BR 9809793	A	20000627	BR 1998-9793	19980514
NZ 501069	A	20000728	NZ 1997-501069	19980514
US 6121319	A	20000919	US 1998-78935	19980514
JP 2001524986	T2	20011204	JP 1998-549498	19980514
NO 9905543	A	20000110	NO 1999-5543	19991112

MX 9910404 A 20000630 MX 1999-10404 19991112  
 PRIORITY APPLN. INFO.: US 1997-47020P P 19970514  
 WO 1998-US9773 W 19980514


AB This invention is a method and compn. for the inhibition of VCAM-1, and in particular for the treatment of cardiovascular or inflammatory disease, including atherosclerosis, that includes the administration of an effective amt. of an ester of probucol. Rabbits were fed high fat chow (0.5% cholesterol and 3% coconut oil) contg. 0.5% probucol monosuccinate (I) for 3wk. I caused a significant redn. in all lipoprotein fractions.

IT 216167-82-7

RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (monoesters of probucol for treatment of cardiovascular and  
 inflammatory disease)

RN 216167-82-7 CAPLUS

CN Butanedioic acid, mono[4-[[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenyl] ester (9CI) (CA INDEX NAME)



=> d ibib abs hitstr 10

L24 ANSWER 10 OF 14 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1998:761875 CAPLUS

DOCUMENT NUMBER: 130:13646

TITLE: Preparation of phenolic compounds for the inhibition of the expression of VCAM-1

INVENTOR(S): Medford, Russell M.; Somers, Patricia K.; Hoong, Lee K.; Meng, Charles Q.

PATENT ASSIGNEE(S): Atherogenics, Inc., USA

SOURCE: PCT Int. Appl., 109 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 4

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9851662	A2	19981119	WO 1998-US9781	19980514
WO 9851662	A3	20000302		
W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
AU 9874851	A1	19981208	AU 1998-74851	19980514
AU 750041	B2	20020711		
EP 994853	A2	20000426	EP 1998-922264	19980514

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
 IE, SI, LT, LV, FI, RO

US 6121319	A	20000919	US 1998-78935	19980514
BR 9809819	A	20010918	BR 1998-9819	19980514
JP 2002503227	T2	20020129	JP 1998-549502	19980514
NO 9905544	A	20000110	NO 1999-5544	19991112
MX 9910402	A	20000630	MX 1999-10402	19991112

PRIORITY APPLN. INFO.: US 1997-47020P P 19970514  
 WO 1998-US9781 W 19980514

OTHER SOURCE(S): MARPAT 130:13646  
 GI



AB Title compds. [e.g., I; R = Z1Z2R5; R1,R2 = (un)substituted (cyclo)alkyl, -(hetero)aryl, etc.; R3,R4 = any group that does not otherwise adversely affect (sic) the desired properties of the mol. including H, halogen, or R1 (sic); R5 = (di)(alkyl)amino, alkyl, alkoxy(carbonyl), (hetero)aryl, etc.; Z1 = O SOO-2, NH, CH2; Z2 = bond, alkylene(oxy) aryleneoxy, etc.] were prepd. Thus, 4-(BrCH2)C6H4CH2CO2H was thioetherified by 4-mercapto-2,6-di-tert-butylphenol to give I [R = SCH2C6H4(CH2CO2H)-4, R1 = R2 = CMe3, R3 = R4 = H]. Data for biol. activity of I were given.


IT 216167-80-5P 216167-81-6P 216167-82-7P  
 216167-83-8P 216167-84-9P 216167-85-0P  
 216167-86-1P 216167-88-3P 216167-89-4P  
 216167-90-7P 216167-91-8P 216167-92-9P  
 216167-93-0P 216167-94-1P 216167-95-2P  
 216167-96-3P 216167-97-4P 216167-98-5P  
 216167-99-6P 216168-00-2P 216168-01-3P  
 216168-02-4P 216168-03-5P 216168-05-7P  
 216168-07-9P 216168-14-8P 216168-18-2P  
 216168-20-6P 216168-22-8P 216168-24-0P  
 216168-26-2P 216168-27-3P 216168-28-4P  
 216168-29-5P 216168-30-8P 216168-31-9P  
 216168-32-0P 216168-33-1P 216168-34-2P  
 216168-35-3P 216168-36-4P 216168-37-5P  
 216168-38-6P 216168-39-7P 216168-41-1P  
 216168-42-2P 216168-43-3P 216168-44-4P  
 216168-47-7P 216168-48-8P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (prepn. of phenolic compds. for the inhibition of the expression of VCAM-1)

RN 216167-80-5 CAPLUS


CN Pentanedioic acid, 4-[[[1-[[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenyl methyl ester (9CI) (CA INDEX NAME)






RN 216167-81-6 CAPLUS

CN Phenol, 4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-[(4-nitrophenyl)methoxy]phenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)




RN 216167-82-7 CAPLUS

CN Butanedioic acid, mono[4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenyl] ester (9CI) (CA INDEX NAME)




RN 216167-83-8 CAPLUS

CN 2-Furancarboxylic acid, 5-nitro-, 4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenyl ester (9CI) (CA INDEX NAME)




RN 216167-84-9 CAPLUS

CN Butanoic acid, 4-[4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-dimethylphenoxy]- (9CI) (CA INDEX NAME)




RN 216167-85-0 CAPLUS

CN Phenol, 4-[[1-[[4-(4-aminobutoxy)-3,5-dimethylphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)




RN 216167-86-1 CAPLUS

CN Phenol, 4-[[1-[[4-(4-aminobutoxy)-3,5-bis(1,1-dimethylethyl)phenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)




RN 216167-88-3 CAPLUS


CN Butanoic acid, 4-hydroxy-, 4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenyl ester (9CI) (CA INDEX NAME)




RN 216167-89-4 CAPLUS  
 CN 2-Butanone, 1-[4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenoxy]-3,3-dimethyl- (9CI)  
 (CA INDEX NAME)




RN 216167-90-7 CAPLUS  
 CN Phenol, 4-[[1-[[4-(4-aminobutoxy)phenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)




RN 216167-91-8 CAPLUS  
 CN Butanoic acid, 4-[4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]phenoxy]- (9CI) (CA INDEX NAME)




RN 216167-92-9 CAPLUS  
 CN Acetic acid, [4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenoxy]- (9CI) (CA INDEX NAME)




RN 216167-93-0 CAPLUS  
 CN Glycine, 4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenyl ester (9CI) (CA INDEX NAME)




RN 216167-94-1 CAPLUS  
 CN Pentanedioic acid, mono[4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenyl] ester (9CI) (CA INDEX NAME)



RN 216167-95-2 CAPLUS  
 CN Butanoic acid, 4-[4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenoxy]- (9CI) (CA INDEX NAME)




RN 216167-96-3 CAPLUS  
 CN Oxiranemethanol, .alpha.-[[4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenoxy]methyl]- (9CI) (CA INDEX NAME)




RN 216167-97-4 CAPLUS

CN Oxiranemethanol, 3-[[4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenoxy]methyl]- (9CI) (CA INDEX NAME)




RN 216167-98-5 CAPLUS

CN Oxiranemethanol, .alpha.-[[[3-[[4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenoxy]methyl]oxiranyl]methoxy]methyl]- (9CI) (CA INDEX NAME)




RN 216167-99-6 CAPLUS

CN Phenol, 4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-(oxiranylmethoxy)phenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)




RN 216168-00-2 CAPLUS

CN Glycine, N-[3-[4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenoxy]-2-hydroxypropyl]-(9CI) (CA INDEX NAME)




RN 216168-01-3 CAPLUS

CN 1,2,3-Butanetriol, 4-[4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenoxy]-(9CI) (CA INDEX NAME)



RN 216168-02-4 CAPLUS


CN Phenol, 4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-(3-ethoxy-2-hydroxypropoxy)phenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)-(9CI) (CA INDEX NAME)



RN 216168-03-5 CAPLUS


CN 1,2-Propanediol, 3-[4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-

hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenoxy]-  
(9CI) (CA INDEX NAME)



RN 216168-05-7 CAPLUS


CN Phenol, 4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-ethoxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)



RN 216168-07-9 CAPLUS


CN 2-Propenoic acid, 3-[4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenoxy]-, ethyl ester, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 216168-14-8 CAPLUS

CN Phenol, 4-[[1-[[4-[2-[4-(dimethylamino)phenyl]ethoxy]-3,5-bis(1,1-dimethylethyl)phenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)




RN 216168-18-2 CAPLUS

CN L-Arginine, N2-[4-[4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenoxy]-1,4-dioxobutyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

NH<sub>2</sub>

RN 216168-20-6 CAPLUS

CN 2-Propenoic acid, 3-[4-[[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenoxy]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 216168-22-8 CAPLUS

CN .alpha.-D-Galactopyranose, 6-O-[4-[[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenyl]-1,2:3,4-bis-O-(1-methylethylidene)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.






RN 216168-24-0 CAPLUS

CN Phenol, 4-[[1-[[4-[3-(dimethylamino)propoxy]-3,5-bis(1,1-dimethylethyl)phenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)-(9CI) (CA INDEX NAME)



RN 216168-26-2 CAPLUS


CN Glycine, N-[[4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenoxy]acetyl]- (9CI) (CA INDEX NAME)



RN 216168-27-3 CAPLUS

CN L-Glutamic acid, N-[[4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenoxy]acetyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 216168-28-4 CAPLUS


CN L-Glutamic acid, N-[3-[4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenoxy]-2-hydroxypropyl]-, diethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 216168-29-5 CAPLUS

CN 2-Propenoic acid, 4-[4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenoxy]butyl ester (9CI) (CA INDEX NAME)



RN 216168-30-8 CAPLUS


CN Phenol, 4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-(4-hydroxybutoxy)phenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)



RN 216168-31-9 CAPLUS


CN .beta.-D-Glucopyranose, 6-O-[4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenyl]-, 1,2,3,4-tetraacetate (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 216168-32-0 CAPLUS


CN 1H-Tetrazole-1-butanoic acid, 4-[[[1-[[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenyl ester (9CI) (CA INDEX NAME)



RN 216168-33-1 CAPLUS

CN Phenol, 4-[[[1-[[[3,5-bis(1,1-dimethylethyl)-4-[[[(1E)-3-hydroxy-1-propenyl]oxy]phenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)-(9CI) (CA INDEX NAME)


Double bond geometry as shown.




RN 216168-34-2 CAPLUS

CN L-Lysine, N2-[[[4-[[[1-[[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenoxy]acetyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 216168-35-3 CAPLUS

CN D-Glucose, 6-O-[4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 216168-36-4 CAPLUS


CN D-Glucitol, 6-O-[4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 216168-37-5 CAPLUS

CN Butanoic acid, 4-[[hydroxy(2-hydroxyphenoxy)phosphinyloxy]-, 4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenyl ester (9CI) (CA INDEX NAME)




RN 216168-38-6 CAPLUS

CN Butanoic acid, 4-hydroxy-3,3-dimethyl-, 4-[[[1-[[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenyl] ester (9CI) (CA INDEX NAME)




RN 216168-39-7 CAPLUS

CN Butanoic acid, 4-(sulfooxy)-, 1-[4-[[[1-[[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenyl] ester (9CI) (CA INDEX NAME)




RN 216168-41-1 CAPLUS


CN Butanoic acid, 4-amino-4-oxo-, 4-[[[1-[[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenyl] ester (9CI) (CA INDEX NAME)



RN 216168-42-2 CAPLUS


CN Butanedioic acid, mono[4-[[[1-[[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenyl] ester (9CI) (CA INDEX NAME)






RN 216168-43-3 CAPLUS

CN Butanedioic acid, 4-[[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenyl methyl ester (9CI)  
(CA INDEX NAME).




RN 216168-44-4 CAPLUS

CN Pentanoic acid, 5-[4-[[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenoxy]-2,3-dihydroxybutyl]- (9CI) (CA INDEX NAME)



RN 216168-47-7 CAPLUS


CN Glycine, N-[4-[4-[[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenoxy]-2,3-dihydroxybutyl]- (9CI) (CA INDEX NAME)



RN 216168-48-8 CAPLUS

CN L-Lysine, N6-[3-[4-[[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenoxy]-2-hydroxypropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



IT 216168-52-4P 216168-53-5P 216168-54-6P  
 216168-55-7P 216168-57-9P 216168-58-0P  
 216168-59-1P 216168-60-4P 216168-61-5P  
 216168-62-6P 216168-63-7P 216168-66-0P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (prepn. of phenolic compds. for the inhibition of the expression of  
 VCAM-1)


RN 216168-52-4 CAPLUS

CN Butanoic acid, 4-[4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-dimethylphenoxy]-, methyl ester (9CI) (CA INDEX NAME)




RN 216168-53-5 CAPLUS

CN 1H-Isoindole-1,3(2H)-dione, 2-[4-[4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-dimethylphenoxy]butyl]- (9CI) (CA INDEX NAME)




RN 216168-54-6 CAPLUS

CN 1H-Isoindole-1,3(2H)-dione, 2-[4-[4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenoxy]butyl]- (9CI) (CA INDEX NAME)




RN 216168-55-7 CAPLUS

CN 1H-Isoindole-1,3(2H)-dione, 2-[4-[4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]phenoxy]butyl]- (9CI) (CA INDEX NAME)




RN 216168-57-9 CAPLUS

CN Acetic acid, [4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenoxy]-, ethyl ester (9CI) (CA INDEX NAME)



RN 216168-58-0 CAPLUS


CN 2H-Isoindole-2-acetic acid, 1,3-dihydro-1,3-dioxo-, 4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenyl ester (9CI) (CA INDEX NAME)






RN 216168-59-1 CAPLUS

CN Butanoic acid, 4-[4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenoxy]-, methyl ester  
(9CI) (CA INDEX NAME)



RN 216168-60-4 CAPLUS


CN Glycine, N-[[4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenoxy]acetyl]-, ethyl ester  
(9CI) (CA INDEX NAME)



RN 216168-61-5 CAPLUS

CN L-Glutamic acid, N-[[4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenoxy]acetyl]-, diethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 216168-62-6 CAPLUS


CN L-Lysine, N2-[[4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenoxy]acetyl]-, methyl ester  
(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 216168-63-7 CAPLUS

CN Butanedioic acid, 2,2-dimethyl-, 4-[4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenyl] ester (9CI) (CA INDEX NAME)



RN 216168-66-0 CAPLUS

CN Butanoic acid, 4-[4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]phenoxy]-, methyl ester (9CI) (CA INDEX NAME)



=> d ibib abs hitstr 9

L24 ANSWER 9 OF 14 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1999:48609 CAPLUS

DOCUMENT NUMBER: 130:119591

TITLE: Antioxidant enhancement of therapy for hyperproliferative conditions

INVENTOR(S): Chinery, Rebecca; Beauchamp, R. Daniel; Coffey, Robert J.; Medford, Russell M.; Wadsinski, Brian

PATENT ASSIGNEE(S): Atherogenics, Inc., USA

SOURCE: PCT Int. Appl., 112 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.

KIND DATE

APPLICATION NO. DATE

WO 9901118	A2	19990114	WO 1998-US13750	19980701
WO 9901118	A3	19990422		
W: AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GE, HU, ID, IL, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9882827	A1	19990125	AU 1998-82827	19980701
EP 1019034	A2	20000719	EP 1998-933078	19980701
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002511878	T2	20020416	JP 1999-507360	19980701
US 2001049349	A1	20011206	US 2001-779086	20010207
PRIORITY APPLN. INFO.:				
			US 1997-886653	A 19970701
			US 1997-967492	A 19971111
			US 1998-108609	B1 19980701
			WO 1998-US13750	W 19980701

OTHER SOURCE(S): MARPAT 130:119591

AB A method to enhance the cytotoxic activity of an antineoplastic drug comprises administering an effective amt. of the antineoplastic drug to a host exhibiting abnormal cell proliferation in combination with an effective cytotoxicity-increasing amt. of an antioxidant. The invention also includes a method to decrease the toxicity to an antineoplastic agent or increase the therapeutic index of an antineoplastic agent administered for the treatment of a solid growth of abnormally proliferating cells, comprising administering an antioxidant prior to, with, or following the antineoplastic treatment.


IT 216167-82-7 216167-94-1 219773-26-9  
219773-27-0 219773-28-1 219773-29-2  
219773-30-5

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(antioxidant enhancement of therapy for hyperproliferative conditions)


RN 216167-82-7 CAPLUS

CN Butanedioic acid, mono[4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenyl] ester (9CI) (CA INDEX NAME)




RN 216167-94-1 CAPLUS

CN Pentanedioic acid, mono[4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenyl] ester (9CI) (CA INDEX NAME)




RN 219773-26-9 CAPLUS

CN Hexanedioic acid, mono[4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenyl] ester (9CI) (CA INDEX NAME)




RN 219773-27-0 CAPLUS

CN Octanedioic acid, mono[4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenyl] ester (9CI) (CA INDEX NAME)




RN 219773-28-1 CAPLUS

CN Decanedioic acid, mono[4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenyl] ester (9CI) (CA INDEX NAME)



RN 219773-29-2 CAPLUS


CN Nonanedioic acid, mono[4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenyl] ester (9CI) (CA INDEX NAME)



RN 219773-30-5 CAPLUS

CN 2-Butenedioic acid (2Z)-, mono[4-[[[1-[[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenyl] ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.



=> d ibib abs hitstr 8

L24 ANSWER 8 OF 14 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2000:335659 CAPLUS

DOCUMENT NUMBER: 132:343330

TITLE: Methods and compositions to lower plasma cholesterol levels

INVENTOR(S): Medford, Russell M.; Saxena, Uday

PATENT ASSIGNEE(S): Atherogenics, Inc., USA

SOURCE: PCT Int. Appl., 50 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000028332	A1	20000518	WO 1999-US26519	19991109
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1137948	A1	20011004	EP 1999-962732	19991109
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				

IE, SI, LT, LV, FI, RO  
JP 2002529740 T2 20020910  
PRIORITY APPLN. INFO.:

JP 2000-581459 19991109  
US 1998-107644P P 19981109  
WO 1999-US26519 W 19991109

AB A method for detg. whether a compd. binds to a lipoprotein, e.g. LDL or VLDL, in a manner which will lower plasma cholesterol is provided that includes assessing the ability of the compd. to form a complex with the lipoprotein, e.g., LDL or VLDL, and then detg. whether the newly formed complex causes a change in the structure of apoB-100 that results in increased binding affinity to the LDL receptor. Also disclosed is a method for lowering cholesterol in a host in need thereof, including a human, that includes the administration of an effective amt. of a compd. which binds to cholesterol-carrying lipoprotein (e.g. LDL or VLDL) in a manner that alters the three dimensional configuration of the lipoprotein and increases the binding affinity of the apoB-100 protein to the LDL receptor, including those on the surface of a hepatic cell.


IT 216167-82-7 216167-84-9 216167-91-8  
216167-93-0 216167-94-1 216167-95-2  
216168-35-3 216168-36-4 216168-42-2  
268738-49-4

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(methods and compns. to lower plasma cholesterol levels)


RN 216167-82-7 CAPLUS

CN Butanedioic acid, mono[4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenyl] ester (9CI) (CA INDEX NAME)




RN 216167-84-9 CAPLUS

CN Butanoic acid, 4-[4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-dimethylphenoxy]- (9CI) (CA INDEX NAME)




RN 216167-91-8 CAPLUS


CN Butanoic acid, 4-[4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]phenoxy]- (9CI) (CA INDEX NAME)




RN 216167-93-0 CAPLUS  
 CN Glycine, 4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenyl ester (9CI) (CA INDEX NAME)



RN 216167-94-1 CAPLUS  
 CN Pentanedioic acid, mono[4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenyl] ester (9CI) (CA INDEX NAME)




RN 216167-95-2 CAPLUS  
 CN Butanoic acid, 4-[4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenoxy]- (9CI) (CA INDEX NAME)



RN 216168-35-3 CAPLUS  
 CN D-Glucose, 6-O-[4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 216168-36-4 CAPLUS


CN D-Glucitol, 6-O-[4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 216168-42-2 CAPLUS

CN Butanedioic acid, mono[4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-dimethylphenyl] ester (9CI) (CA INDEX NAME)



RN 268738-49-4 CAPLUS

CN Pentonic acid, 5-O-[4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenyl]- (9CI) (CA INDEX NAME)





REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d ibib abs hitstr 7

L24 ANSWER 7 OF 14 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2001:713364 CAPLUS

DOCUMENT NUMBER: 135:267271

TITLE: Probucol-related thioketals and thioethers for inhibiting the expression of VCAM-1, preparation, and therapeutic use

INVENTOR(S): Meng, Charles Q.; Hoong, Lee K.; Somers, Patricia K.

PATENT ASSIGNEE(S): Atherogenics, Inc., USA

SOURCE: PCT Int. Appl., 58 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 4

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001070757	A2	20010927	WO 2001-US9049	20010321
WO 2001070757	A3	20020314		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

EP 1289944	A2	20030312	EP 2001-920617	20010321
------------	----	----------	----------------	----------


R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

PRIORITY APPLN. INFO.: US 2000-191046P P 20000321

WO 2001-US9049 W 20010321

OTHER SOURCE(S): MARPAT 135:267271

GI



AB Probucol-related thioketals and thioethers are provided that inhibit the expression of VCAM-1, and which can be used in the treatment of VCAM-1-mediated diseases, including inflammatory disorders, cardiovascular diseases, ocular diseases, autoimmune diseases, neurol. disorders, and cancer. Compds. of the invention include I [Ra-Rd = H, (un)substituted alkyl, (un)substituted aryl, etc.; Z = (un)substituted carbohydrate, (un)substituted alditol, (un)substituted C1-10 alkyl terminated by sulfonic acid, etc.]. The compds. also can be used to treat hyperlipidemia and/or hypercholesterolemia. Compd. prepn. is described.

IT 362598-43-4P 362598-44-5P 362598-45-6P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(probucol-related thioketals and thioethers for inhibiting VCAM-1 expression, prepn., and therapeutic use)

RN 362598-43-4 CAPLUS

CN Arabinitol, 5-O-[4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenyl]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 362598-44-5 CAPLUS


CN D-Ribose, 5-O-[4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 362598-45-6 CAPLUS

CN 1-Propanesulfonic acid, 3-[4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenoxy]-2-hydroxy- (9CI) (CA INDEX NAME)



IT 362598-26-3 362598-28-5 362598-30-9

362598-32-1 362598-34-3 362598-36-5


362598-38-7 362598-40-1 362598-42-3

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(probucol-related thioketals and thioethers for inhibiting VCAM-1 expression, prepn., and therapeutic use)


RN 362598-26-3 CAPLUS

CN Butanoic acid, 3-amino-4-[4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenoxy]-(9CI) (CA INDEX NAME)




RN 362598-28-5 CAPLUS

CN Pentanoic acid, 3-amino-5-[4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenoxy]-(9CI) (CA INDEX NAME)




RN 362598-30-9 CAPLUS

CN Acetic acid, [4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenoxy]difluoro- (9CI) (CA INDEX NAME)




RN 362598-32-1 CAPLUS

CN Phosphonic acid, [[4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenoxy]methyl]- (9CI) (CA INDEX NAME)




RN 362598-34-3 CAPLUS  
 CN Phosphonic acid, [[4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenoxy]difluoromethyl]- (9CI) (CA INDEX NAME)




RN 362598-36-5 CAPLUS  
 CN L-Proline, 1-[2-[4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenoxy]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 362598-38-7 CAPLUS  
 CN Phenol, 4-[[[1-[[3,5-bis(1,1-dimethylethyl)-4-(2-pyridinylmethoxy)phenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)




RN 362598-40-1 CAPLUS

CN Phenol, 4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-(3-pyridinylmethoxy)phenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)



RN 362598-42-3 CAPLUS

CN Phenol, 4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-(5-pyrimidinylmethoxy)phenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)



IT 362598-46-7



RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(probucol-related thioketals and thioethers for inhibiting VCAM-1 expression, prepn., therapeutic use, and use with other agents)

RN 362598-46-7 CAPLUS

CN D-Gluconic acid, 3-[4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenoxy]-2-hydroxypropyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



=> file stnguide  
COST IN U.S. DOLLARS

FULL ESTIMATED COST

SINCE FILE	TOTAL
ENTRY	SESSION
47.13	425.90

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

CA SUBSCRIBER PRICE

SINCE FILE	TOTAL
ENTRY	SESSION
-5.86	-18.88

FILE 'STNGUIDE' ENTERED AT 11:45:12 ON 25 MAY 2003  
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT  
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE  
AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.  
LAST RELOADED: May 23, 2003 (20030523/UP).

=> d his

(FILE 'HOME' ENTERED AT 11:12:32 ON 25 MAY 2003)

FILE 'REGISTRY' ENTERED AT 11:12:42 ON 25 MAY 2003

L1	STRUCTURE UPLOADED	
L2	7 S	L1
L3	105 S	L1 FULL
L4	0 S	C39 H44 F2 O6 S2 . X NA AND L3
L5	1 S	C39 H44 F2 O6 S2 . X NA/MF AND L3

FILE 'CAPLUS' ENTERED AT 11:16:19 ON 25 MAY 2003

L6	1 S	L5
	S L5 AND	C37 H60 O7 S2/MF

FILE 'REGISTRY' ENTERED AT 11:18:38 ON 25 MAY 2003

L7	5 S	C37 H60 O7 S2/MF
----	-----	------------------

FILE 'CAPLUS' ENTERED AT 11:18:39 ON 25 MAY 2003

L8	6 S	L7
L9	0 S	L5 AND L8

FILE 'REGISTRY' ENTERED AT 11:18:44 ON 25 MAY 2003

L10            0 S L5 AND        C37 H60 O7 S2/MF  
 L11            3 S L3 AND        C37 H60 O7 S2/MF  
  
 FILE 'CAPLUS' ENTERED AT 11:19:21 ON 25 MAY 2003  
 L12            4 S L11  
  
 FILE 'REGISTRY' ENTERED AT 11:22:09 ON 25 MAY 2003  
 L13            1 S L3 AND        C36 H58 O4 S2/MF  
  
 FILE 'CAPLUS' ENTERED AT 11:24:33 ON 25 MAY 2003  
 L14            1 S L13  
               S L3 AND C35 H54 O4 S2/MF  
  
 FILE 'REGISTRY' ENTERED AT 11:25:55 ON 25 MAY 2003  
 L15            7 S C35 H54 O4 S2/MF  
  
 FILE 'CAPLUS' ENTERED AT 11:25:56 ON 25 MAY 2003  
 L16            6 S L15  
 L17            5 S L3 AND L16  
  
 FILE 'REGISTRY' ENTERED AT 11:28:26 ON 25 MAY 2003  
 L18            14 S    216167-80-5 OR 216167-81-6 OR 216167-82-7 OR    216167-83-8  
 L19            3 S    216167-82-7 OR 216167-80-5 OR 216167-84-9  
  
 FILE 'CAPLUS' ENTERED AT 11:32:42 ON 25 MAY 2003  
 L20            9 S L19  
  
 FILE 'REGISTRY' ENTERED AT 11:33:34 ON 25 MAY 2003  
 L21            11 S 216167-93-0 OR 216167-94-1 OR 216167-95-2 OR    216167-96-3 O  
  
 FILE 'CAPLUS' ENTERED AT 11:37:46 ON 25 MAY 2003  
               S 216167-93-0/REG#  
  
 FILE 'REGISTRY' ENTERED AT 11:38:41 ON 25 MAY 2003  
 L22            1 S 216167-93-0/RN  
  
 FILE 'CAPLUS' ENTERED AT 11:38:42 ON 25 MAY 2003  
 L23            3 S L22  
 L24            14 S L3

FILE 'STNGUIDE' ENTERED AT 11:45:12 ON 25 MAY 2003

=> file reg

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.24	426.14
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	0.00	-18.88

FILE 'REGISTRY' ENTERED AT 11:47:47 ON 25 MAY 2003  
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
 COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 23 MAY 2003 HIGHEST RN 519387-75-8  
 DICTIONARY FILE UPDATES: 23 MAY 2003 HIGHEST RN 519387-75-8

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2003

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details:  
<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=> s l3 and 6-12/o

3220667 6-12/O

L25 34 L3 AND 6-12/O

=> d scan


L25 34 ANSWERS REGISTRY COPYRIGHT 2003 ACS

IN L-Arginine, N2-[4-[4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenoxy]-1,4-dioxobutyl]- (9CI)

MF C41 H64 N4 O6 S2

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

—NH<sub>2</sub>

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> s l25 not n/els

14921990 N/ELS

L26 27 L25 NOT N/ELS

=> d scan




L26 27 ANSWERS REGISTRY COPYRIGHT 2003 ACS

IN Butanoic acid, 4-(sulfooxy)-, 1-[4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenyl] ester (9CI)

MF C35 H54 O7 S3

CI COM



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):10

L26 27 ANSWERS REGISTRY COPYRIGHT 2003 ACS

IN D-Altritol, 1-O-[4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenyl]- (9CI)

MF C37 H60 O7 S2

Absolute stereochemistry.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L26 27 ANSWERS REGISTRY COPYRIGHT 2003 ACS

IN D-erythro-Hexonic acid, 2,4-dideoxy-6-O-[4'-fluoro-5-[[1-[[4'-fluoro-6-hydroxy-5-(1-methylethyl)[1,1'-biphenyl]-3-yl]thio]-1-methylethyl]thio]-3-(1-methylethyl)[1,1'-biphenyl]-2-yl]-, sodium salt (9CI)

MF C39 H44 F2 O6 S2 . x Na


Absolute stereochemistry.



● x Na


L26 27 ANSWERS REGISTRY COPYRIGHT 2003 ACS  
 IN D-Ribose, 5-O-[4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenyl]- (9CI)  
 MF C36 H56 O6 S2

Absolute stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L26 27 ANSWERS REGISTRY COPYRIGHT 2003 ACS  
 IN Butanoic acid, 4-(sulfooxy)-, 1-[4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenyl] ester, monosodium salt (9CI)  
 MF C35 H54 O7 S3 . Na



● Na

ACCESSION NUMBER: 1998:761875 CAPLUS  
 DOCUMENT NUMBER: 130:13646  
 TITLE: Preparation of phenolic compounds for the inhibition of the expression of VCAM-1  
 INVENTOR(S): Medford, Russell M.; Somers, Patricia K.; Hoong, Lee K.; Meng, Charles Q.  
 PATENT ASSIGNEE(S): Atherogenics, Inc., USA  
 SOURCE: PCT Int. Appl., 109 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 4  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9851662	A2	19981119	WO 1998-US9781	19980514
WO 9851662	A3	20000302		
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9874851	A1	19981208	AU 1998-74851	19980514
AU 750041	B2	20020711		
EP 994853	A2	20000426	EP 1998-922264	19980514
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
US 6121319	A	20000919	US 1998-78935	19980514
BR 9809819	A	20010918	BR 1998-9819	19980514
JP 2002503227	T2	20020129	JP 1998-549502	19980514
NO 9905544	A	20000110	NO 1999-5544	19991112
MX 9910402	A	20000630	MX 1999-10402	19991112
PRIORITY APPLN. INFO.:			US 1997-47020P	P 19970514
			WO 1998-US9781	W 19980514
OTHER SOURCE(S):		MARPAT 130:13646		

=> d hitstr 5

L28 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2003 ACS


IT **216167-98-5P 216168-36-4P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of phenolic compds. for the inhibition of the expression of VCAM-1)

RN 216167-98-5 CAPLUS

CN Oxiranemethanol, .alpha.-[[[3-[[4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenoxy]methyl]oxiranyl]methoxy]methyl]- (9CI) (CA INDEX NAME)



RN 216168-36-4 CAPLUS

CN D-Glucitol, 6-O-[4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

